1. Biochemistry and Chemical Biology
  2. Chromosomes and Gene Expression

Mutations in SKI in Shprintzen–Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization

  1. Ilaria Gori
  2. Roger George
  3. Andrew G Purkiss
  4. Stephanie Strohbuecker
  5. Rebecca A Randall
  6. Roksana Ogrodowicz
  7. Virginie Carmignac
  8. Laurence Faivre
  9. Dhira Joshi
  10. Svend Kjær
  11. Caroline S Hill  Is a corresponding author
  1. Developmental Signalling Laboratory, The Francis Crick Institute, United Kingdom
  2. Structural Biology Facility, The Francis Crick Institute, United Kingdom
  3. Bioinformatics and Biostatistics Facility, The Francis Crick Institute, United Kingdom
  4. INSERM - Université de Bourgogne UMR1231 GAD, FHU-TRANSLAD, France
  5. Peptide Chemistry Facility, The Francis Crick Institute, United Kingdom
https://doi.org/10.7554/eLife.63545
Share this article
Cite this article
  1. Ilaria Gori
  2. Roger George
  3. Andrew G Purkiss
  4. Stephanie Strohbuecker
  5. Rebecca A Randall
  6. Roksana Ogrodowicz
  7. Virginie Carmignac
  8. Laurence Faivre
  9. Dhira Joshi
  10. Svend Kjær
  11. Caroline S Hill
(2021)
Mutations in SKI in Shprintzen–Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization
eLife 10:e63545.
https://doi.org/10.7554/eLife.63545
  2. Download BibTeX
  3. Download .RIS

Abstract

Shprintzen–Goldberg syndrome (SGS) is a multisystemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys–Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. In SGS patients, heterozygous point mutations have been mapped to the transcriptional co-repressor SKI, which is a negative regulator of TGF-β signaling that is rapidly degraded upon ligand stimulation. The molecular consequences of these mutations, however, are not understood. Here we use a combination of structural biology, genome editing, and biochemistry to show that SGS mutations in SKI abolish its binding to phosphorylated SMAD2 and SMAD3. This results in stabilization of SKI and consequently attenuation of TGF-β responses, both in knockin cells expressing an SGS mutation and in fibroblasts from SGS patients. Thus, we reveal that SGS is associated with an attenuation of TGF-β-induced transcriptional responses, and not enhancement, which has important implications for other Marfan-related syndromes.

Introduction

Shprintzen–Goldberg syndrome (SGS) is a multisystemic connective tissue disorder. Common features observed in SGS patients include craniofacial, skeletal, and cardiovascular anomalies, ranging from heart valve defects to thoracic aortic aneurysms, all of which are also characteristic of Marfan syndrome (MFS) and Loeys–Dietz syndrome (LDS) (Cook et al., 2015a; Verstraeten et al., 2016; Loeys et al., 2005; Williams et al., 2007). In addition, SGS patients present with craniosynostosis, intellectual disability, and skeletal muscle hypotonia (Shprintzen and Goldberg, 1982; Glesby and Pyeritz, 1989; Greally et al., 1998). All three syndromes have been linked to deregulation of the transforming growth factor β (TGF-β) signaling pathway (Cannaerts et al., 2015).

The TGF-β family of ligands comprises the TGF-βs themselves, Activins, Nodal, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs) and they play pleiotropic roles in embryonic development and tissue homeostasis. In addition, their signaling is deregulated in diverse pathologies (Miller and Hill, 2016). They exert their action by binding to type I and type II serine/threonine kinase receptors at the cell surface (TGFBR1 and TGFBR2, respectively, for the TGF-βs) (Massagué, 2012). In the resulting ligand-bound heterotetrameric receptor complex, the type II receptor phosphorylates and activates the type I receptor, which in turn phosphorylates the intracellular mediators, the receptor-regulated SMADs (R-SMADs). Once phosphorylated, the R-SMADs (SMAD2 and SMAD3 in the case of TGF-β, Activin, and Nodal) associate with the common mediator of the pathway, SMAD4. The resulting heterotrimeric complexes accumulate in the nucleus where they interact with other transcriptional regulators to activate or repress target gene expression (Massagué, 2012). Two highly related co-repressors, SKI and SKIL (formerly known as SnoN), act as negative regulators in the pathway (Deheuninck and Luo, 2009; see below).

The role of deregulated TGF-β signaling in Marfan-related syndromes is controversial. MFS is caused by loss-of-function mutations in the extracellular matrix protein, Fibrillin 1 (FBN1) (Dietz et al., 1991). These mutations are thought to increase the bioavailability of TGF-β ligands, as FBN1 binds the latent form of the TGF-βs (Neptune et al., 2003; Kaartinen and Warburton, 2003). Supporting the idea that excessive TGF-β signaling contributes to the manifestations of MFS, a TGF-β neutralizing antibody significantly improved the lung phenotype in a mouse model of MFS (homozygous Fbn1mgΔ) (Neptune et al., 2003; Cannaerts et al., 2015) and reduced the occurrence of aortic aneurysms in the Fbn1C1039G/+ mouse model of MFS (Habashi et al., 2006). Contradicting these results, others have shown that the aortopathy in the Fbn1C1039G/+ mouse model is not mediated by excessive TGF-β signaling and in fact is exacerbated by loss of TGF-β signaling in smooth muscle cells (Wei et al., 2017). Furthermore, TGF-β signaling protects against abdominal aortic aneurysms in angiotensin II-infused mice (Angelov et al., 2017). This controversy emphasizes the importance of understanding exactly how TGF-β signaling is impacted in MFS. Furthermore, the related syndrome LDS is caused by pathogenic mutations in several different components of the TGF-β pathway, TGFBR1, TGFBR2, SMAD2, SMAD3, and the ligands, TGFB2 and TGFB3. These mutations all cause missense amino acid substitutions that have been either verified in vitro, or are predicted to be loss of function, implying that LDS is caused by attenuated TGF-β signaling (Horbelt et al., 2010; Cardoso et al., 2012; Schepers et al., 2018). However, paradoxically, histological and biochemical studies of aortic tissue derived from LDS patients reveal an apparent high TGF-β signaling signature (van de Laar et al., 2012; Gallo et al., 2014; Lindsay et al., 2012). SGS is caused by mutations in SKI, and both SMAD-mediated and non-SMAD-mediated TGF-β signaling has been reported to be increased in primary dermal fibroblasts from SGS patients (Doyle et al., 2012).

The co-repressors SKI and SKIL play important roles in a number of different cellular processes including proliferation, differentiation, transformation, and tumor progression (Bonnon and Atanasoski, 2012). They are dimeric proteins that interact with both phosphorylated SMAD2 and SMAD3 (PSMAD2 or PSMAD3) via short motifs at their N-termini, and with SMAD4 via a SAND domain (named after Sp100, AIRE-1, NucP41/75, DEAF-1) in the middle of both proteins (Deheuninck and Luo, 2009). Between these two domains lies a Dachshund homology domain (DHD), which is thought to also be important for R-SMAD binding (Wilson et al., 2004; Ueki and Hayman, 2003). SKI and SKIL both contain a leucine zipper domain in their C-termini, through which they dimerize (Deheuninck and Luo, 2009). They are negative regulators of TGF-β/Activin signaling, with two distinct mechanisms of regulation having been proposed. In one model, SKI and SKIL bind with SMAD4 to SMAD binding elements (SBEs) of TGF-β/Activin target genes, and recruit co-repressors such as NCOR1 or SIN3A (Tokitou et al., 1999; Nomura et al., 1999; Stroschein et al., 1999; Deheuninck and Luo, 2009). They thus maintain the transcription of these target genes suppressed in the absence of signal. Upon TGF-β/Activin signaling, SKI and SKIL are rapidly degraded by the E3 ubiquitin ligase, RNF111 (formerly known as Arkadia), a process that requires SKI/SKIL binding to PSMAD2 or PSMAD3 (Le Scolan et al., 2008; Levy et al., 2007; Nagano et al., 2007). This then allows the activated SMAD3–SMAD4 complexes to bind the exposed SBEs and activate target gene transcription (Levy et al., 2007; Stroschein et al., 1999). In the competing model, SKI and SKIL act as repressors of active signaling simply by binding to PSMAD2 or PSMAD3 and SMAD4 in such a way as to disrupt the activated PSMAD2/PSMAD3–SMAD4 complexes (Luo, 2004; Ueki and Hayman, 2003; Wu et al., 2002). The heterozygous missense mutations that cause SGS have been mapped in SKI to the N-terminal R-SMAD-binding domain, with some small deletions and point mutations also found in the DHD, which is also necessary for R-SMAD binding (Carmignac et al., 2012; Doyle et al., 2012; Schepers et al., 2015). Thus, depending on the mechanism whereby SKI inhibits TGF-β/Activin signaling, loss of the interaction with PSMAD2/PSMAD3 would be predicted to have opposite effects on signaling output. If the PSMAD2/PSMAD3 interaction is required for SKI degradation, its loss would inhibit TGF-β signaling. However, if SKI binding to PSMAD2/PSMAD3 disrupts active SMAD complexes, then its loss would promote TGF-β signaling.

Here we use a combination of genome editing, structural biology, biochemistry, and analysis of patient samples to elucidate the molecular mechanism underlying SGS and to resolve the paradox surrounding the role of TGF-β signaling in Marfan-related syndromes. We first determine at the molecular level how SKI/SKIL function in the TGF-β/Activin signaling pathways and show that an intact ternary phosphorylated R-SMAD–SMAD4 complex is required for ligand-induced SKI/SKIL degradation. We demonstrate that the SGS mutations in SKI abolish interaction with PSMAD2 and PSMAD3 and this results in an inability of SKI to be degraded in response to TGF-β/Activin signaling. We go on to show that SKI stabilization results in an attenuation of the TGF-β transcriptional response in both knockin HEK293T cells and fibroblasts from SGS patients. Our work unequivocally establishes that SGS mutations lead to an attenuated TGF-β response, which has major implications for all the Marfan-related syndromes.

Results

A PSMAD2/3–SMAD4 ternary complex is essential for TGF-β/Activin-induced degradation of SKI/SKIL

To understand the consequences of SKI mutations in SGS and to resolve the paradox surrounding the function of TGF-β signaling in Marfan-related syndromes, we first set out to determine exactly how SKI and SKIL act as negative regulators of TGF-β and Activin signaling. We and others have previously demonstrated that SKI and SKIL are rapidly degraded upon TGF-β/Activin stimulation by the E3 ubiquitin ligase RNF111, and this requires PSMAD2 or PSMAD3 (Le Scolan et al., 2008; Levy et al., 2007; Nagano et al., 2007). Knockdown experiments suggested that SMAD4 was not necessary (Levy et al., 2007), but we subsequently showed that tumor cells deleted for SMAD4 or containing mutations in SMAD4 that abolish interactions with activated R-SMADs, abrogated TGF-β-induced degradation of SKI/SKIL (Briones-Orta et al., 2013). Whether the requirement for SMAD4 was direct or indirect was not clear.

To define the role of SMAD4 in SKI/SKIL degradation, we used CRISPR/Cas9 technology to delete SMAD4 in transformed embryonic kidney cells HEK293T, which express both SKI and SKIL, and in the human keratinocyte cell line, HaCaT, which predominantly express SKIL (Levy et al., 2007; Figure 1—source data 1). In wild-type (WT) cells, TGF-β/Activin induced rapid SKI and SKIL degradation, compared to cells treated with the TGFBR1 inhibitor, SB-431542 (Inman et al., 2002; Figure 1A,B). Deletion of SMAD4 in multiple clones of both cell types abolished ligand-induced SKI/SKIL degradation (Figure 1A,B). We validated these SMAD4-null cell lines by demonstrating that transient expression of SMAD4 could rescue TGF-β/Activin-induction of the SMAD3–SMAD4 reporter, CAGA12-Luciferase (Figure 1—figure supplement 1A,B). Furthermore, we could show that loss of SMAD4 inhibited the ligand-induced expression of a number of endogenous TGF-β and BMP target genes (Figure 1—figure supplement 1C). By knocking out SMAD2 or SMAD3 individually or together, we also confirmed that these R-SMADs are absolutely required for TGF-β/Activin-induced degradation of SKI and SKIL and act redundantly (Figure 1C; Figure 1—source data 1). Thus, R-SMADs and SMAD4 are all essential for TGF-β/Activin-dependent SKI/SKIL degradation.

Figure 1 with 1 supplement see all
Download asset Open asset
Requirement of SMAD2 or SMAD3 and SMAD4 for SKI and SKIL degradation.

(A and C) The parental HEK293T cell line and two individual SMAD4 knockout clones (A) or two individual SMAD2, SMAD3 knockout clones, or two SMAD2 and SMAD3 double knockout clones (C) were incubated overnight with 10 μM SB-431542, washed out, then incubated with full media containing either SB-431542 or 20 ng/ml Activin A for 1 hr, as indicated. Whole-cell extracts were immunoblotted with the antibodies indicated. (B) Parental HaCaT and four individual SMAD4 knockout clones were treated as above, except that they were treated with 2 ng/ml TGF-β for 1 hr instead of Activin A. Nuclear lysates were immunoblotted using the antibodies indicated. SB, SB-431542; A, Activin A; T, TGF-β; S2, SMAD2; S3, SMAD3; S2/3, SMAD2 and SMAD3; S4, SMAD4; KO, knockout; dKO, double knockout.

Figure 1—source data 1

Sequences of knockout alleles made in HEK293T cells.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig1-data1-v2.docx

In addition to forming a ternary complex with PSMAD2 or PSMAD3, SMAD4 has also been shown to interact directly with SKI and SKIL through their SAND domains (Walldén et al., 2017; Wu et al., 2002). To determine which of these SMAD4 interactions were important for TGF-β/Activin-induced SKI/SKIL degradation, we stably reintroduced enhanced GFP (EGFP) fusions of WT or mutated SMAD4 into HaCaT SMAD4-null cells. We selected two missense mutations on opposite faces of the C-terminal Mad homology 2 (MH2) domain of SMAD4: Asp351->His (D351H) and Asp537-->Tyr (D537Y) (Shi et al., 1997). These have been shown to occur naturally in the human colorectal cancer cell lines CACO-2 and SW948, and have lost the ability to bind phosphorylated R-SMADs (De Bosscher et al., 2004). In addition, we used the crystal structure of the MH2 domain of SMAD4 and the SAND domain of SKI, to design two mutations Ala433-->Glu (A433E) and Ile435-->Tyr (I435Y), that would be expected to abolish SMAD4 binding to SKI and SKIL (Wu et al., 2002).

We confirmed that these SMAD4 mutants behaved as expected in the rescue cell lines by testing their interaction with SKIL and R-SMADs by immunoprecipitation. As endogenous RNF111 triggers SKIL degradation in TGF-β/Activin-dependent manner, the stable SMAD4-expressing HaCaT rescue cell lines were incubated with the proteasome inhibitor, MG-132 for 3 hr prior to TGF-β stimulation, to block SKIL degradation. As predicted, the D351H and D537Y SMAD4 mutants had lost their ability to bind SMAD2 upon TGF-β induction, but retained the interaction with SKIL. By contrast, A433E and I435Y SMAD4 mutants were unable to bind SKIL, but could interact with SMAD2 upon TGF-β stimulation (Figure 2A). Furthermore, as expected, D351H and D537Y SMAD4 mutants failed to rescue the ability of TGF-β to induce expression of CAGA12-Luciferase in HaCaT SMAD4-null cells or rescue TGF-β-induced transcription of target genes, but the A433E and I435Y SMAD4 mutants rescued these responses almost as well as WT SMAD4 (Figure 2—figure supplement 1A,B).

Figure 2 with 1 supplement see all
Download asset Open asset
Characterization of the role of SMAD4 in TGF-β-induced SKIL degradation.

(A–C) HaCaT SMAD4 knockout (S4 KO) cells were stably transfected with EGFP alone, or EGFP SMAD4 (WT) or with four different EGFP-SMAD4 mutants (D351H, D537Y, which abolish interaction with the R-SMADs, and A433E and I435Y, which do not interact with SKIL). (A) Cells were incubated overnight with 10 µM SB-431542, washed out and pre-incubated with 25 μM MG-132 for 3 hr, and then treated either with 10 μM SB-431542 or 2 ng/ml TGF-β for 1 hr. Whole-cell extracts were immunoprecipitated (IP) with GFP-trap agarose beads. The IPs were immunoblotted using the antibodies shown. Inputs are shown below. (B) Nuclear lysates were prepared from the HaCaT S4 KO cells stably transfected with EGFP alone or with EGFP-SMAD4 constructs as indicated, treated as in (A), but without the MG-132 step and immunoblotted using the antibodies shown. On the right the quantifications are the normalized average ± SEM of five independent experiments. The quantifications are expressed as fold changes relative to SB-431542-treated S4 KO cells. (C) Levels of SKIL in the EGFP-positive S4 KO rescue cell lines treated as in (B), assayed by flow cytometry. Each panel shows an overlay of the indicated treatment conditions. The red line indicates the SB-431542-treated sample, whereas the cyan line indicates the TGF-β-treated sample. Quantifications are shown bottom right. For each group, the percentage of the median fluorescence intensity normalized to the SB-431542-treated sample is quantified. Data are the mean ± SEM of five independent experiments. The p-values are from one-way ANOVA with Sidak’s post hoc correction *p<0.05; ****p<0.0001. SB, SB-431542; T, TGF-β.

Figure 2—source data 1

Quantification of Western blot for HaCaT S4 KO rescue cell lines, as presented in Figure 2B.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig2-data1-v2.xlsx
Figure 2—source data 2

Flow cytometry data for HaCaT S4 KO rescue cell lines, as presented in Figure 2C.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig2-data2-v2.xlsx

Having demonstrated that these mutants behaved as designed, we asked which were able to mediate TGF-β-induced SKIL degradation, using three different assays. In a Western blot assay using nuclear extract, we found that reintroduction of WT SMAD4 in SMAD4-null cells caused a 50% reduction in SKIL levels in TGF-β-induced cells compared to those treated with SB-431542 (Figure 2B). However, none of the four SMAD4 mutants could rescue TGF-β-induced SKIL degradation (Figure 2B). We then established a flow cytometry assay to quantify SKIL protein stability in EGFP/EGFP-SMAD4-expressing cells (Figure 2C; Figure 2—figure supplement 1C). Treatment with TGF-β for 1 hr caused a 52% reduction in the relative median fluorescence intensity in the EGFP-SMAD4 WT-expressing cells, reflecting SKIL levels, compared to cells treated with SB-431542 (Figure 2C). However, for all four SMAD4 mutants tested, the median fluorescence was not decreased by TGF-β treatment (Figure 2C). Finally, we used an immunofluorescence analysis to monitor SKIL protein stability following TGF-β exposure. SMAD4-null cells showed strong nuclear staining of SKIL in the non-signaling condition (SB-431542), which remained unchanged by TGF-β treatment (Figure 3). Reintroduction of WT EGFP-SMAD4 conferred the ability to degrade SKIL upon TGF-β treatment, whereas none of the mutant SMAD4s were able to rescue SKIL degradation (Figure 3, arrows). Thus, all three assays demonstrate that a ternary R-SMAD–SMAD4 complex is absolutely necessary for TGF-β-induced SKIL degradation, as is the ability of SMAD4 to interact with SKIL itself. This suggests that within a canonical activated ternary SMAD complex, the R-SMAD component binds to the N-terminal region of SKIL/SKI, whilst SMAD4 binds the SAND domain, and both interactions are absolutely required for SKIL/SKI degradation.

Figure 3
Download asset Open asset
Visualization of TGF-β-induced SKIL degradation.

HaCaT SMAD4 knockout (S4 KO) cells or those stably expressing EGFP SMAD4 WT or EGFP SMAD4 mutants were incubated overnight with 10 μM SB-431542, washed out, and incubated for 1 hr with 10 µM SB-431542 or with 2 ng/ml TGF-β. Cells were fixed and stained for EGFP (for SMAD4), SKIL, and with DAPI (blue) to mark nuclei and imaged by confocal microscopy. The merge combines SKIL, SMAD4, and DAPI staining. Arrows indicate examples of EGFP-expressing cells and corresponding levels of nuclear SKIL. Scale bar corresponds to 50 µm.

SGS mutations inhibit the interaction of SKI with phosphorylated R-SMADs

We next investigated the consequences of the SGS mutations on SKI and SKIL’s ability to interact with the R-SMADs. SKI and SKIL share a highly conserved region at their N-terminus comprising the domain known to be important for R-SMAD binding (Deheuninck and Luo, 2009; Figure 4—figure supplement 1A). We first determined the minimal region of SKI required for R-SMAD binding using peptide pulldown assays with biotinylated SKI peptides and whole-cell extract from uninduced and TGF-β-treated HaCaT cells. This revealed that amino acids 11–45 of SKI are sufficient for binding to PSMAD2 and PSMAD3 upon TGF-β stimulation, whilst the unphosphorylated SMADs did not bind to any of the SKI peptides (Figure 4—figure supplement 1B). SMAD4 is also pulled down in these assays in a ligand-induced manner, by virtue of its interaction with the phosphorylated R-SMADs.

The SGS mutations discovered so far mostly cluster within this 11–45 region of SKI and a few deletions and point mutations have additionally been mapped in the DHD domain (Carmignac et al., 2012; Doyle et al., 2012; Schepers et al., 2015). The residues mutated are completely conserved, both between species, and also in the related protein, SKIL (Figure 4—figure supplement 1A; Carmignac et al., 2012). To determine the effect of these mutations on R-SMAD interaction, we introduced six different SGS mutations into the SKI peptide 11–45 and showed that they all prevented binding of PSMAD2 and PSMAD3, and as a result, also SMAD4 (Figure 4A). These results were also confirmed with the equivalent mutations in SKIL (Figure 4B). We proved that the interaction with SMAD2 was mediated via its MH2 domain using a mouse embryonic fibroblast cell line that expresses a truncated SMAD2 protein comprising just the MH2 domain (Piek et al., 2001; Das et al., 2009; Figure 4C). We confirmed this using recombinant human phosphorylated SMAD2 MH2 domain produced in insect cells by co-expressing the SMAD2 MH2 domain with the kinase domain of TGFBR1 (Figure 4D). In both cases, the SGS mutations prevented interaction of the SKI peptide with the SMAD2 MH2 domain.

Figure 4 with 1 supplement see all
Download asset Open asset
SGS mutations inhibit binding of SKI to SMAD2/3.

(A and B) HaCaT cells were treated or not with 2 ng/ml TGF-β. A peptide pulldown assay was performed on whole cells extracts and pulldowns were immunoblotted with the antibodies indicated. Inputs are shown on the right. (A) Wild-type (WT) SKI peptides corresponding to amino acids 11–45 or containing SGS point mutations as shown in red were used. (B) WT SKIL peptides corresponding amino acids 80–120 or containing mutations (in red) corresponding to SGS mutations in SKI were used. (C) WT SKI peptides or those containing SGS point mutations were used in pulldown assays with whole-cell extracts of SMAD2-null mouse embryonic fibroblasts that express just the MH2 domain of SMAD2 (MEF SMAD2Δex2) (Das et al., 2009), treated with 2 ng/ml TGF-β. The untreated sample is only shown for the WT SKI peptide. A PSMAD2 immunoblot is shown. (D) A recombinant trimer of phosphorylated SMAD2 MH2 domain was used in a peptide pulldown assay with WT and G34D SKI peptides. A PSMAD2 immunoblot is shown, with inputs on the right. (E) Mutational peptide array of SKI peptides (amino acids 11–45), mutated at all residues between amino acids 19 and 35, was probed with a recombinant PSMAD3–SMAD4 complex, which was visualized using a SMAD2/3 antibody conjugated to Alexa 488. On each row, the indicated amino acid is substituted for every other amino acid. A representative example is shown. See Figure 4—figure supplement 1C and Figure 4—source data 2 for quantification of the peptide arrays.

Figure 4—source data 1

Peptide sequences for peptide array.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig4-data1-v2.pdf
Figure 4—source data 2

Quantification of peptide arrays.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig4-data2-v2.xlsx

We next used a peptide array to gain a better understanding of which amino acids can be tolerated at the positions found to be mutated in SGS and to determine which other amino acids in this region of SKI are essential for the R-SMAD interaction. The SKI peptide corresponding to amino acids 11–45 was synthesized as an array on a cellulose sheet such that each residue in the sequence between residues 19 and 35 was substituted with all 19 alternative amino acids (Figure 4E; Figure 4—source data 1). The array was probed with a recombinant PSMAD3–SMAD4 trimer, generated by co-expressing SMAD3 and SMAD4 with the TGFBR1 kinase domain in insect cells. The PSMAD3–SMAD4 complex was then detected using a fluorescently-labeled SMAD2/3 antibody. Eight residues are intolerant to almost any amino acid substitution (Thr20, Leu21, Phe24, Ser28, Ser31, Leu32, Gly34, and Pro35). Strikingly, six of these residues are the amino acids known to be mutated in SGS patients, and the array results readily explain why these residues are mutated to a number of different amino acids in SGS (Figure 4E; for quantification, see Figure 4—figure supplement 1C and Figure 4—source data 2). In addition, Thr20 and Phe24 are also crucial residues for binding the PSMAD3–SMAD4 complex, but have not yet been reported as disease mutations. Mutations in the other nine amino acids do not impair the binding, and almost any other amino acid apart from proline can be tolerated at these positions.

Crystal structure of the SKI peptide with the phosphorylated SMAD2 MH2 domain

To discover why these eight amino acids were so crucial for R-SMAD binding, and also to understand why SKI and SKIL only recognize phosphorylated R-SMADs, we solved the crystal structure of the SKI peptide (amino acids 11–45) with a phosphorylated homotrimer of the SMAD2 MH2 domain, produced in insect cells as described above. We confirmed using SEC-MALLS that the phosphorylated SMAD2 MH2 domain was indeed trimeric in solution (Figure 5—figure supplement 1A). Analysis of the binding affinity of the SKI peptide to the SMAD2 MH2 domain trimer indicated that the dissociation constant (Kd) was in the low nanomolar range (Figure 5—figure supplement 1B). The structure was determined by molecular replacement and refined at 2 Å resolution and readily explained why the crucial amino acids identified in the peptide were required for SMAD2 binding (Figure 5; Figure 5—figure supplement 1C).

Figure 5 with 1 supplement see all
Download asset Open asset
Crystal structure of PSMAD2 MH2 domain and N-terminal SKI peptide.

(A) Crystal structure of the phosphorylated SMAD2 MH2 domain trimer (the three monomers are shown in bright green, cyan, and olive) with the N-terminal SKI peptide amino acids 11–45 (magenta). A ribbon representation is shown. The C-terminal phosphates are indicated with a ball and stick representation (red and magenta). (B–F) Close ups on key residues for SKI binding. SKI residues are shown in magenta, and SMAD2 residues are in green. In (B–D), a ribbon representation is shown. In (E and F), SMAD2 is shown as a surface representation and SKI as a ribbon. (G) A detail from the structure of monomeric SMAD2 MH2 domain with a peptide from ZFYVE9 (formerly called SARA) (Wu et al., 2000). Note that the β1’ strand that contains Tyr268 is locked in a hydrophobic pocket, forcing Trp448 into flattened orientation, incompatible with SKI binding. (H) A detail from the structure in (A) indicating how SMAD2 complex formation shifts the position of the β1’ strand and more particularly, Tyr268, allowing Trp448 to flip 90°, enabling it to stack with SKI residues Phe24 and Pro35.

Figure 5—source data 1

Structure validation report for crystal structure (ID: 6ZVQ).

https://cdn.elifesciences.org/articles/63545/elife-63545-fig5-data1-v2.pdf

The SKI peptide binds on the outside face of the MH2 domain at the so-called three helix bundle, comprising helices 3, 4, and 5 (Wu et al., 2001; Figure 5A). The N-terminal helix of SKI packs against helix 3 of SMAD2, and the C-terminal portion of the SKI peptide, which contains the critical Gly34 and Pro35, forms a sharp turn that is stabilized by pi-stacking coordination between Phe24 of SKI, Trp448 of SMAD2, and Pro35 of SKI (Figure 5B). Moreover, the NE1 of the Trp448 side chain forms a H-bond to the main chain carbonyl group of Gly33, which in turn positions Pro35 for the interaction with Trp448 (Figure 5B). Furthermore, Glu270 in SMAD2 provides a pocket, which has a negatively charged base that ties down SKI Gly34 through hydrogen-bonding to its main chain amides. Other key interactions involving amino acids identified above as crucial for binding include the main chain carbonyl of Ser31, which forms a hydrogen bond to the ND1 of Asn387 in helix 3 (Figure 5C), and the hydroxyl group of SKI Thr20, which forms a hydrogen bond with the Gln455 at the end of helix 5 of SMAD2, and is nearly completely buried in the interface (Figure 5D). The two leucine residues (Leu21 and Leu32) that are mutated in SGS are both buried in the structure (Figure 5E,F). The structure we obtained is consistent with a SKI–SMAD2 MH2 domain structure that was published by others, while this work was in progress (Miyazono et al., 2018). In that case, a pseudo-phosphorylated SMAD2 MH2 domain produced in Escherichia coli was used, complexed with a SKI peptide containing a C-terminal acidic tag (Ser-Asp-Glu-Asp).

Since our structure was generated with phosphorylated SMAD2, we were able to explore why SKI only binds phosphorylated R-SMADs and not monomeric unphosphorylated R-SMADs. To do this we compared the structure of the unphosphorylated SMAD2 MH2 domain bound to a region of ZFYVE9 (formerly called SARA) (Wu et al., 2000) with our current structure of phosphorylated SMAD2 MH2 domain complexed with SKI. It was clear that in the unphosphorylated SMAD2 structure, Tyr268 in the so-called β1’ strand (amino acids 261–274) is locked in a stable conformation in a hydrophobic pocket, and also forms a number of hydrogen bonds (Figure 5G). Crucially, this conformation forces Trp448 into flattened orientation, which is incompatible with SKI binding through the pi-stacking involving SKI Phe24, SMAD2 Trp448, and SKI Pro35 (Figure 5G). MH2 domain trimerization generates a new binding site for the β1’ strand on the adjacent MH2 domain subunit (Figure 5H; Video 1). The central residue driving this is Tyr268. In the trimer, the hydroxy group of Tyr268 makes hydrogen bond contact with the carbonyl group of Asp450 and the main chain of Lys451 on the adjacent MH2 domain subunit. As a consequence, Trp448 moves into an upright position in the trimer, allowing engagement with SKI. Thus, SKI can only bind SMAD2 in its phosphorylated trimeric state.

Video 1
Download asset
Mechanism of SKI binding to phosphorylated SMAD2 MH2 domain.

Animation of SMAD2 MH2 domain monomer (orange) forming a complex with two other SMAD2 MH2 domain monomers (cyan and olive). Note the movement of Trp448 on helix five and Tyr268 on the β1’ strand in the orange monomer upon trimerization. The flipped Trp448 is then in the correct orientation for binding to the SKI peptide (magenta).

Knockin of an SGS mutation into HEK293T cells inhibits Activin-induced SKI degradation and attenuates PSMAD3–SMAD4-mediated transcriptional activity

We have shown that the presence of SGS mutations prevent the interaction of SKI/SKIL with phosphorylated R-SMADs and have demonstrated that SKI/SKIL degradation requires an activated R-SMAD–SMAD4 complex. We therefore went on to investigate the functional effect of the SGS mutations on SKI degradation and TGF-β/Activin-induced transcriptional responses. To do this, we chose to focus on Pro35 because of its crucial role in forming the stacking interaction with Trp448 in SMAD2. In SGS patients, Pro35 is mutated to Ser or Gln (Carmignac et al., 2012; Doyle et al., 2012; Schepers et al., 2015), substitutions not tolerated in activated R-SMAD–SMAD4 binding (Figure 4E).

We used CRISPR/Cas9 technology with a single-stranded template oligonucleotide to knock in the Pro35 → Ser (P35S) mutation into HEK293T cells, and we efficiently generated a number of homozygous clones (Figure 6—figure supplement 1A). In three independent clonal cell lines carrying the P35S SKI mutation, the binding to endogenous phosphorylated SMAD2 was severely compromised, compared with WT SKI (Figure 6A). The binding to SMAD4, however, was unchanged in the mutant cell lines, as the SGS mutations do not affect the SKI SAND domain, which is responsible for SMAD4 binding (Figure 6A). To assess the impact of the P35S SKI mutation on the SKI and SKIL degradation, cells were treated with Activin for 1 or 2 hr and SKI/SKIL levels determined by immunoblotting. At both time points, we clearly demonstrated that P35S SKI levels remained stable, whilst in the parental cell lines, SKI protein is almost entirely degraded after 1 hr of Activin treatment (Figure 6B). The presence of mutated SKI had no effect on the Activin-induced degradation of SKIL in these lines (Figure 6B). Thus, the P35S mutation renders SKI completely resistant to ligand-induced degradation.

Figure 6 with 1 supplement see all
Download asset Open asset
Knockin of an SGS mutation into SKI in HEK293T cells inhibits SKI degradation and inhibits Activin-induced transcription.

(A) Parental HEK293T and three independent P35S SKI knockin clones were incubated overnight with 10 μM SB-431542, washed out, and treated for 3 hr with 25 μM MG-132 and then with either SB-431542 or 20 ng/ml Activin A for an additional 1 hr. Whole-cell lysates were immunoprecipitated (IP) with SKI antibody or beads alone (Be). The IPs were immunoblotted using the antibodies shown. Inputs are shown below. (B) Parental HEK293T and four independent P35S SKI knockin clones were incubated with 10 μM SB-431542 overnight, washed out, and incubated with either SB-431542 or 20 ng/ml Activin for the times indicated. Whole-cell lysates were immunoblotted using the antibodies indicated. (C) Cells were treated as in (B), and nuclear lysates were prepared and analyzed by DNA pulldown assay using the wild-type c-Jun SBE oligonucleotide or a version mutated at the SMAD3–SMAD4 binding sites (top panel). Inputs are shown in the bottom panel. HEK293T parental and two independent P35S SKI knockin clones were stably transfected with the CAGA12-Luciferase reporters (D) or the BRE-Luciferase reporter (E) with TK-Renilla as an internal control. Cells were serum starved with media containing 0.5% fetal bovine serum and 10 μM SB-431542 overnight. Subsequently, cells were washed and treated with Activin A (D) or BMP4 (E) at the concentrations indicated for 8 hr. Cell lysates were prepared and assayed for Luciferase and Renilla activity. Plotted are the means and SEM of seven (D) or four (E) independent experiments, with the ratio of Luciferase:Renilla shown. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The p-values are from two-way ANOVA with Tukey’s post hoc test. A, Activin; SB, SB-431542; Par, parental.

Figure 6—source data 1

Luciferase assays for Activin A-induced HEK293T P35S SKI clones, as presented in Figure 6D.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig6-data1-v2.xlsx
Figure 6—source data 2

Luciferase assays for BMP4-induced HEK293T P35S SKI clones, as presented in Figure 6E.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig6-data2-v2.xlsx

To determine whether SGS mutations had the same effect in SKIL, we introduced a G103V mutation into SKIL, corresponding to the SGS mutation G34V in SKI (referred to as SKIL ΔS2/3). Transfection of G103V SKIL in HEK293T cells led to reduction of SMAD2 binding in parental cells (Figure 6—figure supplement 1B). The residual binding was mediated via SMAD2’s interaction with SMAD4, as it was lost in the SMAD4 knockout cells (Figure 6—figure supplement 1B). Binding of SMAD4 in the absence or presence of signal was unaffected by the mutation. As observed above for SKI, the SGS mutation in SKIL led to resistance to Activin-induced degradation (Figure 6—figure supplement 1C), indicating that the R-SMAD interaction was essential. In addition, we made a version of SKIL with mutations in the SAND domain (R314A, T315A, H317A, and W318E) that rendered it unable to interact with SMAD4 (referred to as SKIL ΔS4). This mutant was also not degraded upon Activin stimulation (Figure 6—figure supplement 1C), demonstrating an essential requirement for SMAD4 binding.

SKI and SKIL bind DNA in conjunction with SMAD4 at SBEs of TGF-β/Activin target genes in the absence of ligand stimulation. The ligand-induced degradation of SKI and SKIL then allows the activated R-SMAD–SMAD4 complexes access to the SBEs to activate transcription of target genes (Levy et al., 2007; Stroschein et al., 1999). We hypothesized that if the SGS mutations render SKI resistant to ligand-induced degradation, then mutant SKI and SMAD4 would remain bound to the DNA. To test this, we used a DNA pulldown assay with an oligonucleotide corresponding to SBEs from the JUN promoter (Levy et al., 2007). Consistent with our prediction, both WT and P35S SKI bound the SBEs with SMAD4 in the absence of signal, but after Activin stimulation, the binding of WT SKI is lost, whilst the binding of P35S SKI is retained (Figure 6C).

The SKI–SMAD4 complex bound to SBEs in the absence of signal are transcriptionally repressive (Levy et al., 2007; Stroschein et al., 1999). Since P35S SKI remains bound with SMAD4 in Activin-stimulated cells, we reasoned that this would inhibit Activin-induced gene expression. To address this, we stably expressed luciferase reporters (CAGA12-Luciferase and BRE-Luciferase), together with TK-Renilla as an internal control (Dennler et al., 1998; Korchynskyi and ten Dijke, 2002), in parental HEK293T cells and in two independent clones of the knockin P35S SKI cells. The CAGA12-Luciferase reporter responds to TGF-β and Activin, is induced by PSMAD3–SMAD4 complexes, and is sensitive to SKI and SKIL levels, whilst the BRE-Luciferase reporter is induced by SMAD1/5–SMAD4 complexes in response to BMPs and is not affected by SKI and SKIL (Levy et al., 2007). Strikingly, we found a significant reduction in Activin-induced CAGA12-Luciferase activity in the P35S SKI cells compared to the parental cell line (Figure 6D), while BMP4-induced BRE-Luciferase activity was similar in all cell lines (Figure 6E). The results indicate that SGS mutations in SKI lead to inhibition of TGF-β/Activin-induced transcription mediated by PSMAD3–SMAD4 complexes.

Dermal fibroblasts from SGS patients exhibit an attenuated transcriptional TGF-β response

To gain further insights into the functional consequences of the SGS mutations, we obtained dermal fibroblasts from two SGS patients: a female carrying the heterozygous point mutation L32V and a male carrying a heterozygous deletion of 12 base pairs corresponding to codons 94–97 (ΔS94-97) (Carmignac et al., 2012). Both patients present the classical features of SGS such as marfanoid habitus and intellectual disability, whilst the patient-carrying L32V mutation also manifests craniosynostosis. In addition, we obtained dermal fibroblast from a healthy male subject as a control.

We investigated whether the SGS mutations rendered SKI resistant to TGF-β-induced degradation in the dermal fibroblasts, as demonstrated in the knockin HEK293T cells. Indeed, in control fibroblasts, SKI expression is abrogated upon TGF-β stimulation after 1 hr, while in the SGS-derived fibroblasts, SKI protein remains relatively stable (Figure 7A). Note that these cells are heterozygous for the mutation, while the HEK293T P35S SKI knockins used above were homozygous, thus accounting for the incomplete SKI stabilization exhibited by the SGS fibroblasts, compared with the knockin cells.

Figure 7 with 2 supplements see all
Download asset Open asset
SGS mutations in SKI inhibit TGF-β-induced transcriptional responses in fibroblasts derived from SGS patients.

(A) Fibroblasts derived from a healthy subject carrying WT SKI and from two SGS patients carrying the L32V or the ΔS94-97 heterozygous mutations in SKI were incubated overnight with 10 μM SB-431542, washed out, and either re-incubated with SB-431542 or 2 ng/ml TGF-β for the times indicated. Whole-cell lysates were immunoblotted using the antibodies indicated. (B) Hierarchically clustered heatmaps of log2FC values (relative to the SB-431542-treated samples) showing the expression of TGF-β-responsive genes in the healthy fibroblasts and the L32V SKI fibroblasts after 1 hr and 8 hr of TGF-β treatment, analyzed by RNA-seq. Four biological replicates per condition were analyzed. The genes shown are those for which the TGF-β inductions were statistically significant in the healthy fibroblasts, but non-significant in the L32V fibroblasts. (C) The same data as in (B) are presented as box plots. (D) Model for the mechanism of action of WT SKI and mutated SKI. The left panel shows the unstimulated condition. In the nuclei, SKI (blue) is complexed with RNF111 (pink) and is also bound to DNA at SBEs with SMAD4 (green) forming a transcriptionally repressive complex with other transcriptional repressors (maroon). In the middle panel, TGF-β/Activin stimulation induces the formation of phosphorylated R-SMAD–SMAD4 complexes (yellow and green), which induce WT SKI degradation by RNF111. This allows an active PSMAD3–SMAD4 complex to bind SBEs and activate transcription. In the right panel, SGS-mutated SKI (light blue) is not degraded upon TGF-β/Activin stimulation, due to its inability to interact with PSMAD2 or PSMAD3. It therefore remains bound to SMAD4 on DNA, leading to attenuated transcriptional responses.

Figure 7—source data 1

RNA-seq raw data.

https://cdn.elifesciences.org/articles/63545/elife-63545-fig7-data1-v2.xlsx

To determine the effect of SKI stabilization on global TGF-β-induced transcription we performed genome-wide RNA-sequencing (RNA-seq) in three different conditions: SB-431542-treated cells (non-signaling condition), 1 hr TGF-β-treated and 8 hr TGF-β-treated, and compared the L32V and ΔS94-97 SKI fibroblasts to control fibroblasts. The samples separated in a principal component analysis according to the cell line used and the treatment performed (Figure 7—figure supplement 1A), and we confirmed that the differentially enriched genes after TGF-β treatment in the control fibroblasts were characteristic of pathways related to TGF-β signaling (Figure 7—figure supplement 1B). We then performed a pairwise comparison between the TGF-β-treated and SB-431542-treated samples for each of the cell lines individually. We found that of the 339 genes that were differentially expressed in normal fibroblasts after 1 hr of TGF-β treatment, 60% (202 genes) were induced or repressed less efficiently in the L32V mutant fibroblasts, and of these, 97 genes were not significantly differentially expressed in the mutant cells at all (Figure 7—source data 1, Figure 7B,C). After an 8 hr TGF-β induction, we found that 4769 genes were differentially expressed in the normal fibroblasts, and of these 75% (3556 genes) were induced or repressed less efficiently in the L32V mutant cells, and 880 genes were not significantly differentially expressed in the mutant cells at all (Figure 7—source data 1, Figure 7B,C). We observed similar results when comparing the TGF-β responses in the normal fibroblasts versus ΔS94-97 SKI fibroblasts, although the effects were less dramatic (Figure 7—source data 1, Figure 7—figure supplement 1C,D). To illustrate the magnitude of these effects we validated six gene expression profiles (ISLR2, CALB2, SOX11, ITGB6, HEY1, COL7A1) in the normal versus mutant fibroblasts by qPCR (Figure 7—figure supplement 2).

Thus, we conclude that the presence of SGS point mutations in SKI that render it resistant to ligand-induced degradation, result in attenuated TGF-β responses for a substantial subset of target genes.

Discussion

SGS mutations in SKI lead to stabilization of SKI and attenuated TGF-β/Activin transcriptional responses

In this study, we have resolved the mechanism of action of SKI and the related protein SKIL, which has allowed us to elucidate the molecular consequences of SKI mutations in SGS. Our proposed mechanism of how SKI acts as a transcriptional repressor of TGF-β/Activin signaling in health and disease is illustrated in Figure 7D, and our results suggest that the mechanism of action of SKIL is equivalent. In the absence of ligand stimulation, in both healthy and diseased cells, SKI and SKIL bind in conjunction with SMAD4 at SBEs of TGF-β/Activin target genes. Here, they repress transcription by recruiting corepressors such as NCOR1 or SIN3A (Tokitou et al., 1999; Nomura et al., 1999; Stroschein et al., 1999; Deheuninck and Luo, 2009). We and others have also shown that in unstimulated cells, SKI and SKIL interact with the E3 ubiquitin ligase, RNF111, although this binding per se does not lead to SKI/SKIL degradation (Le Scolan et al., 2008; Levy et al., 2007; Nagano et al., 2007). In healthy cells, upon TGF-β/Activin stimulation, SKI/SKIL form a complex with a canonical PSMAD2/PSMAD3–SMAD4 trimer, which induces rapid degradation of SKI/SKIL via RNF111 (Le Scolan et al., 2008; Levy et al., 2007; Nagano et al., 2007). A possible mechanism explaining this would be that the binding of the PSMAD2/PSMAD3–SMAD4 complex induces an activating conformational change in RNF111, although this has not yet been demonstrated. Degradation of SKI and SKIL removes the repressors from the SBEs, allowing access of activated PSMAD3–SMAD4 complexes to the SBEs to regulate transcription of target genes. In SGS cells, mutated SKI can no longer interact with PSMAD2/PSMAD3, and it is therefore not degraded upon TGF-β/Activin signaling. It thus remains bound with SMAD4 to SBEs, resulting in an attenuation of TGF-β/Activin transcriptional responses. To demonstrate the functional consequences of the SGS mutations, we used genome-wide RNA-seq analysis of fibroblasts derived from SGS patients and have shown that SGS mutations indeed lead to a reduction in the magnitude of TGF-β transcriptional responses.

The mechanism underlying SKI and SKIL function

Since the discovery that SKI and SKIL interact with SMAD2 and SMAD3, and act as negative regulators of TGF-β/Activin pathways (Luo et al., 1999; Stroschein et al., 1999; Sun et al., 1999), two different mechanisms of action have been proposed. One mechanism is as described in the paragraph above – an initial version of which was first proposed in 1999 (Stroschein et al., 1999). The second mechanism was based on the crystal structure of the SKI SAND domain with the MH2 domain of SMAD4 (Wu et al., 2002). In this crystal structure, the binding of SKI with SMAD4, which is mediated via the I-loop of the SKI SAND domain with the L3 loop of SMAD4, was mutually exclusive with the binding of SMAD4 to activated R-SMADs, which also requires the L3 loop of SMAD4. Thus, the authors concluded that the mechanism whereby SKI (and by analogy, SKIL) inhibited TGF-β/Activin signaling was by binding to the activated R-SMADs and SMAD4 in such a way as to disrupt the phosphorylated R-SMAD–SMAD4 complexes required for transcriptional activation (Wu et al., 2002). This mechanism has been supported by the observation that overexpression of SKI and SKIL inhibits TGF-β-induced functional responses (Luo, 2004). The two mechanisms are fundamentally different. In the first, SKI and SKIL are constitutive repressors that need to be degraded to allow pathway activation. In the second, SKI and SKIL act as inducible repressors, as they repress only upon ligand induction, by virtue of their ability to disrupt activated SMAD complexes.

Our biochemical analysis of the role of SMAD4 in SKI/SKIL function now resolves the controversy between the two models. First, the efficient SKIL and SKI degradation that we and others have observed upon ligand stimulation in effect rules out the second model, at least in the first hours after ligand induction, as there would be little or no nuclear SKI or SKIL to disrupt activated SMAD complexes. Second, we clearly demonstrate for the first time that an intact functional phosphorylated R-SMAD–SMAD4 trimer is required to bind to SKIL to induce its ligand-dependent degradation. The key piece of evidence for this comes from our analysis of the inability of SMAD4 point mutants to restore ligand-induced SKIL degradation in SMAD4-null HaCaTs. Critically, we show that SMAD4 mutants that cannot form a canonical activated R-SMAD–SMAD4 trimer cannot rescue ligand-induced SKIL degradation, neither can SMAD4 mutants that do not interact with the SAND domain of SKIL. Thus, we conclude that TGF-β/Activin-induced SKIL degradation occurs only when SKIL interacts simultaneously with phosphorylated R-SMADs and with SMAD4, which in turn must interact with each other in a transcriptionally active trimer. This strongly indicates that SKIL binding to the R-SMAD–SMAD4 complex does not disrupt it.

This conclusion is supported by a recent crystal structure of the SAND domain of SKIL with the SMAD4 MH2 domain (Walldén et al., 2017). This structure revealed that SKIL interacts with SMAD4 in two states: an ‘open’ and a ‘closed’ conformation. In the open conformation, the authors showed that SKIL can bind the R-SMAD–SMAD4 complex without intermolecular clashes or further structural readjustment, whereas in the closed state, structural reorganization within the SMAD heterotrimer is required to allow binding of SKIL, as has been observed in the previous structure of SKI with SMAD4 (Wu et al., 2002). Molecular modelling has subsequently confirmed that SKIL in the open conformation forms a stable ternary SKIL–SMAD3–SMAD4 complex (Ji et al., 2019). Furthermore, surface plasmon resonance indicated only one dominant binding mode for SKIL and SMAD4, leading to the conclusion that the open conformation is the biologically and functionally relevant mode and that the closed conformation may be the result of crystal packing forces (Walldén et al., 2017). Note that the residues that allow the binding in the open conformation are highly conserved between SKI and SKIL, suggesting that both repressors bind to an intact activated R-SMAD–SMAD4 complex, which is required for their degradation. This would exclude the disruption model and thus favors the degradation model. It will now be important to solve the structure of an activated R-SMAD–SMAD4 trimer with the N-terminal half of SKI or SKIL that contains the R-SMAD binding motif, the DHD domain and the SAND domain that contacts the SMAD4 moiety. The role of the DHD domain is particularly intriguing as SGS mutations also occur in this domain (Carmignac et al., 2012; Doyle et al., 2012; Schepers et al., 2015) and appear from our patient sample analysis to have a similar effect on inhibiting ligand-induced SKI degradation.

Our structural data also elegantly explain why SKI and SKIL only bind to phosphorylated SMAD2 and SMAD3 in the context of an activated SMAD trimer, and not to monomeric SMAD2 or SMAD3. The key residue for this discrimination is Trp448 in SMAD2, the equivalent of which would be Trp406 in SMAD3. In the trimer, this residue is in a conformation compatible with stacking between Phe24 and Pro35 of SKI. In the monomer, however, it is rotated approximately 90°, prohibiting SKI binding. The binding mode of SKI to SMAD2 is distinct from that of other SMAD2-binding partners, for example, the transcription factor FOXH1, which contains two binding motifs (Miyazono et al., 2018). One of which, the so-called SIM, binds SMAD2 in both monomeric and trimeric forms, whilst the so-called FM only binds phosphorylated trimeric SMAD2 because it recognizes the interface of the SMAD trimer (Miyazono et al., 2018; Randall et al., 2002; Randall et al., 2004). It will be interesting in the future to discover whether any other SMAD2/3-binding partner uses the same mode of interaction as SKI and SKIL.

The molecular mechanism of SGS

As discussed in Introduction, SGS is a Marfan-related syndrome, with patients exhibiting many of the same features characteristic of MFS and LDS. These syndromes have been considered as TGF-β signalopathies, as the causal mutations are either direct components of the TGF-β signaling pathway or, as in the case of MFS, a component of the microfibrils in the ECM, FBN1, that is known to bind latent TGF-β in complex with latent TGF-β binding proteins (LTBPs) (Cannaerts et al., 2015; Ramirez et al., 2004; Robertson et al., 2015). There has been controversy over whether the manifestations of these syndromes result from too little TGF-β signaling, or too much. This is obviously a crucial issue to resolve, as it is influencing the types of treatments being developed for patients with these syndromes.

The first suggestion that MFS resulted from excessive TGF-β came from mouse models, where key phenotypes could be rescued by a TGF-β neutralizing antibody (Habashi et al., 2006; Neptune et al., 2003). However, later studies using a potent murine anti-TGF-β antibody, or genetic methods for reducing TGF-β signaling have not corroborated these findings, and have worsened, rather than improved disease in MFS mouse models (Cook et al., 2015b; Holm et al., 2011; Lindsay et al., 2012; Wei et al., 2017). Furthermore, administration of small-molecule inhibitors of the TGF-β type I receptor, or a pan-TGF-β neutralizing antibody, has been associated with serious adverse cardiovascular toxicities, such as valve defects, similar to those found in MFS (Anderton et al., 2011; Stauber et al., 2014; Mitra et al., 2020). The finding that mutations in FBN1 that prevent binding of LTBPs might result in lower levels of TGF-β signaling, rather than excessive signaling, is not so surprising given the more recent understanding of how TGF-β is activated. In order for mature TGF-β ligands to be released from the latent complex, either force has to be applied via integrins, to partially unfold the cleaved TGF-β pro-domain allowing release of the mature domain, or the pro-domain must be degraded by proteases (Dong et al., 2017; Rifkin et al., 2018; Robertson and Rifkin, 2016). For the traction mechanism to occur, the integrin must be anchored to the actin cytoskeleton, and the LTBP must be tethered to ECM, via FBN1 and fibronectin. Thus, release of latent TGF-β alone is not therefore sufficient to produce active TGF-β ligands.

Consistent with the view that lower levels of TGF-β signaling might be responsible for MFS, the mutations that give rise to LDS are all loss-of-function mutations in TGF-β pathway components (Schepers et al., 2018). Paradoxically though, signatures of higher TGF-β signaling were observed over time in mouse models of LDS (Gallo et al., 2014; MacFarlane et al., 2019). However, in this case, the pathology could not be rescued by neutralizing TGF-β activity. One possibility with both the mouse models of MFS and LDS is that the mutations do initially lead to lowered TGF-β signaling, but over time cells compensate by up-regulating either TGF-β ligands themselves or other TGF-β family ligands that signal through PSMAD2/PSMAD3, ultimately leading to the enhanced signaling signatures observed.

With respect to SGS, there has been much less research into the consequences of the SGS mutations on TGF-β signaling responses. Based on the SMAD complex disruption model of SKI/SKIL action, it has been assumed that loss-of-function mutations in a negative regulator would lead to an increase in TGF-β signaling, and in fact, this has been used to support the idea that the Marfan-related syndromes are caused by excessive TGF-β signaling (Doyle et al., 2012; Gallo et al., 2014). Here we unequivocally show that the opposite is true. We demonstrate that these mutations lead to loss of ligand-induced SKI degradation. As a result, the stabilized SKI remains bound to SBEs with SMAD4 as a repressive complex, and hence, a subset of TGF-β/Activin transcriptional responses are attenuated. We have proven this in both HEK293T knockin cells and patient-derived fibroblasts. Moreover, we also find no evidence for increased PSMAD2 or PSMAD3 signaling. Indeed, neither model of SKI function would actually predict that the SKI mutations would affect levels of phosphorylated R-SMADs, since SKI acts downstream of R-SMAD phosphorylation. Finally, our finding that SGS mutations in SKI lead to its stabilization and are not equivalent to loss of SKI function also explains why patients with 1p36 deletion syndrome, who are haploinsufficient for SKI, do not have SGS. However, unsurprisingly, many of the same organs are affected in both syndromes (Colmenares et al., 2002; Zhu et al., 2013).

It will now be important to use animal models to explore how attenuation of transcription of specific TGF-β/Activin target genes leads to the manifestations of SGS, and to understand why SGS patients exhibit additional defects compared with LDS and MFS patients. We anticipate that our new understanding that the SKI mutations lead to attenuation of TGF-β responses will resolve the paradoxes surrounding the role of aberrant TGF-β signaling in the other Marfan-related disorders and will help inform the development of new therapeutic approaches.

Materials and methods

Cell lines

Request a detailed protocol

HEK293T and HaCaT cells were obtained from the Francis Crick Institute Cell Services and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (Pen/Strep). All CRISPR-Cas9 edited cell lines were cultured in the same media. Dermal fibroblasts from healthy subjects were kindly provided by David Abraham (UCL-Medical School Royal Free Campus) under the ethics of the Health Research Authority, NRES Committee London – Hampstead, Research Ethics Committee (REC) reference, 6398. L32V and ΔS94-97 SKI dermal fibroblasts were obtained from Laurence Faivre and Virginie Carmignac (Université de Bourgogne UMR1231 GAD, Dijon, France) under the ethics of the GAD collection, number DC2011-1332 (Carmignac et al., 2012). The mutations were confirmed by Sanger sequencing and RNA sequencing. The fibroblasts were all cultured in DMEM supplemented with 10% FBS, 1% Pen/Strep, and 1% insulin–transferrin–selenium (Thermo Fisher). Mouse embryo-derived fibroblasts harboring the homozygous null allele Smad2ex2 (MEF SMAD2ex2) (Piek et al., 2001) were maintained in DMEM supplemented with 10% FBS and 1% Pen/Strep. All cell lines have been banked by the Francis Crick Institute Cell Services and certified negative for mycoplasma. The identity of all cell lines was also authenticated by confirming that their responses to ligands and their phenotypes were consistent with published history. All the cell lines are listed in Key Resources Table.

Ligands, chemicals, and cell treatments

Request a detailed protocol

Ligands and inhibitors were used at the following concentrations: TGF-β (PeproTech), 2 ng/ml; Activin A (PeproTech), 20 ng/ml; BMP4 (PeproTech), 20 ng/ml; SB-431542 (Tocris), 10 µM; MG-132 (Tocris), 25 µM. All treatments were performed in full serum or, where required, in serum-starved (0.5% FBS) DMEM. Unless otherwise stated, cells were incubated with 10 µM SB-431542 overnight to inhibit autocrine signalling, then were washed three times with warm media, and stimulated with either Activin A or TGF-β. For proteasome inhibition, cells were treated for 3 hr with 25 µM MG-132 prior stimulation with Activin A or TGF-β.

Plasmids

Plasmids are listed in Key Resources Table. CAGA12-Luciferase, BRE-Luciferase, TK-Renilla, pEGFP-C1, and pEGFP-SMAD4 were as described previously (Dennler et al., 1998; Korchynskyi and ten Dijke, 2002; Levy et al., 2007; Nicolás et al., 2004). The pEGFP-SMAD4 mutants (D351H and D537Y) were generated by swapping the mutated SMAD4 coding region from the EF-HA vector into pEGFP-C1 (De Bosscher et al., 2004). The pEGFP-SMAD4 SMAD4 mutants (A433E and I435Y) were generated by PCR using oligonucleotides listed in Key Resources Table. EF-Flag-SKIL G103V was generated from pEF-FLAG-SKIL by PCR using oligonucleotides listed in Key Resources Table, while the mutant containing the R314A, T315A, H317A, and W318E mutations was generated by synthesizing the SKIL region between BSTEII and AVRII sites containing the mutations and cloning that fragment into pEF-FLAG-SKIL. For plasmids used for generating recombinant proteins, see below.

Transfections, generation of stable cell lines, and reporter assays

Request a detailed protocol

Cells were transfected with the appropriate plasmids using Fugene 6 (Roche) according to the manufacturer’s instructions. Luciferase reporter assays were performed as previously described, using the Dual-Glo assay system (Promega) following the manufacturer's instructions (Levy et al., 2007).

HaCaT SMAD4 KO lines stably expressing either EGFP or EGFP-SMAD4 WT or mutants were generated by transfecting the cells with the appropriate plasmids. Transfected cells were selected with 500 µg/ml of G418 (Invitrogen), then FACS sorted for EGFP-positive cells, and expanded. EGFP expression was confirmed by microscopy. To generate stable HEK293T cell lines expressing either CAGA12-Luciferase or BRE-Luciferase together with TK-Renilla, cells were transfected with the appropriate plasmids together with a plasmid carrying the puromycin resistance gene (pSUPER-retro-puro; OligoEngine). Cells were then selected with 2 μg/ml puromycin (Sigma).

CRISPR/Cas9-mediated knockout of SMADs in HEK293T and HaCaT cells

Request a detailed protocol

For the generation of knockin or knockout HEK293T cells, a parental clone was selected, which was a representative clone from the HEK293T pool that showed a robust Activin-induced SKI degradation and responded to TGF-β family ligands in the same way as the starting pool. For HaCaTs, a pool of cells was used as starting material for knockouts.

For SMAD2 and SMAD3 knockouts, a guide RNA in the MH2 domain of the protein was selected, whereas for SMAD4, two guide RNAs were picked, one targeting the MH1 domain and the other targeting at the end of the MH2 domain. The guide RNAs are shown in Key Resources Table. The guide RNAs were expressed from the plasmid pSpCas9(BB)−2A-GFP (pX458) (Addgene, #48138) (Ran et al., 2013). HEK293T and HaCaT were transfected with the appropriate plasmid, and for the double knockout SMAD2 and SMAD3, the two plasmids were transfected simultaneously. Forty-eight hours after transfection, cells were sorted for EGFP expression, plated as single cells in 96-well plates, and screened by Western blot to assess the loss of the protein. For HEK293Ts, two knockout clones for SMAD2, SMAD3, SMAD2/SMAD3, and SMAD4 were used in these studies. For HaCaTs, four independent SMAD4 knockout clones were used. The sequences of the knockout alleles are shown in Figure 1—source data 1.

Knockin of P35S SKI at the endogenous locus

Request a detailed protocol

To introduce the P35S mutation into SKI, a gRNA was selected immediately downstream of codon 35. A 120 bp ssODN, where the codon CCG (P35) was mutated to TCC (S35) and codons 33 and 34 where silently mutated from GGC to GGA, was made and purified by Sigma (Key Resources Table). The ssODN contained phosphorothioate bonds between the first two and last two nucleotides at the 5′ and 3′ ends, respectively, to avoid ssODN degradation by endogenous nucleases. The silent mutations at codons 33 and 34 were introduced to increase the specificity of the downstream screening primer. The mutation at codon 35 also disrupts the PAM sequence.

Cells were cotransfected with the pX458 plasmid expressing the gRNA and 10 μM ssODN using Fugene 6. After 48 hr, cells were FACS sorted for GFP expression and plated as single cells in 96-well plates. Subsequently, clones were consolidated, and from replicate plates, genomic DNA was extracted using Quickextract DNA extraction solution (Lucigen) according to manufacturer’s instructions. PCR was performed using a universal reverse primer and two different forward primers: a primer which allows detection of WT SKI and one that detects the P35S SKI (Key Resources Table). Clones positive for P35S SKI knockin were selected, verified by Sanger Sequencing, and used for further analysis.

Western blotting, immunoprecipitations, DNA pulldowns, and immunofluorescence

Request a detailed protocol

Whole-cell extracts were prepared as previously described (Inman et al., 2002), while nuclear lysates were prepared according to Wong et al., 1999. Western blots were carried out using standard methods. The list of the antibodies used is shown in Key Resources Table. Immunoprecipitations using GFP-Trap beads (Cromotek) were performed according to the manufacturer’s instructions. Immunoprecipitations using antibodies coupled to protein G-Sepharose beads (Sigma) were as described previously (Levy et al., 2007).

DNA pulldown assays were performed as previously described with some modifications (Levy et al., 2007). Nuclear lysates were extracted using buffer containing 360 mM NaCl, and the DNA pulldowns were performed in the presence of a 40 μg of non-biotinylated mutant oligonucleotide to reduce non-specific binding. The oligonucleotides corresponding to WT and mutated SBE of the JUN promoter are shown in Key Resources Table. Immunofluorescence was performed as previously described (Pierreux et al., 2000), except that cells were washed and fixed for 5 min in methanol at −20 C (Levy et al., 2007). Nuclei were counter stained with DAPI (0.1 µ/ml). Imaging was performed on a Zeiss Upright 780 confocal microscope. Z-stacks were acquired for all channels, and maximum intensity projection images are shown.

For all of these techniques, a representative experiment of at least two biological repeats is shown.

Flow cytometry

Request a detailed protocol

After 1 hr of TGF-β induction, HaCaT SMAD4 KO rescue cells, expressing either EGFP or EGFP-SMAD4 fusions, were washed, trypsinized, and pelleted. Cell pellets were fixed with methanol for 5 min at −20 C. Fixed cells were incubated with primary antibody against SKIL. Cells were then washed three times in phosphate-buffered saline (PBS) and incubated with secondary antibody conjugated with anti-rabbit Alexa 647. As a negative control, we used cells incubated with secondary antibody only. Antibodies used are listed in Key Resources Table. Subsequently, cells were washed three times with PBS, and pellets were resuspended with 500 µl of PBS and filtered to achieve a single-cell suspension. Cells were then analyzed for EGFP fluorescence on an LSRII flow cytometer (BD Biosciences), gated for viable, single cells. We then quantified the fluorescence emitted by Alexa 647 in cells expressing EGFP as a measure of SKIL protein. The FlowJo program was used to analyze the results.

Peptide pulldown assays and peptide array

Request a detailed protocol

For peptide pulldowns, N-terminal biotinylated peptides were synthesized by the Peptide Chemistry Facility at the Francis Crick Institute using standard procedures. The peptide pulldown assays were performed as described previously (Randall et al., 2002). Where recombinant protein was used, it was dissolved in buffer Y (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% [vol/vol] NP-40) and used at the concentrations given in the legend to Figure 4. Peptides sequences are given in Key Resources Table.

A peptide array was generated using peptides corresponding to SKI amino acids 11–45, of which the amino acids 19–35 were mutated one by one to every other amino acid. Arrays were synthesized on an Intavis ResPepSL Automated Peptide Synthesiser (Intavis Bioanalytical Instruments, Germany) on a cellulose membrane by cycles of N(a)-Fmoc amino acids coupling via activation of carboxylic acid groups with diisopropylcarbodiimide in the presence of hydroxybenzotriazole (HOBt), followed by removal of the temporary α-amino protecting group by piperidine treatment. Subsequent to chain assembly, side chain protection groups were removed by treatment of membranes with a deprotection cocktail (20 ml 95% trifluoroacetic acid, 3% triisopropylsilane, 2% water for 4 hr at room temperature) and then washed (4 x dichloromethane, 4 x ethanol, 2 x water, 1 x ethanol), prior to being air dried.

Peptide array membranes were blocked with 5% Milk in 0.01% Tween 20 in PBS and then incubated with purified PSMAD3–SMAD4 complex (see below) overnight. Subsequently, the membranes were washed and incubated with an antibody against SMAD2/3 (BD Biosciences) conjugated to Alexa 488 using a Zenon Mouse IgG Labeling Kit (Life Technology) according to the manufacturer’s instructions. Fluorescence was detected where binding occurred between SKI and PSMAD3–SMAD4 complex and measured with a Typhoon FLA 9500 biomolecular imager (GE Healthcare).

In all peptide experiments, a representative of at least two biological repeats is shown.

Generation of phosphorylated SMAD2 MH2 domain in insect cells

Request a detailed protocol

The cDNA encoding a fusion protein consisting of GST followed by a 3C cleavage site and the human SMAD2 MH2 domain (residues 241–465) was inserted into the MCSI of the pFastBac Dual vector (Thermo Fisher Scientific) in the Sal1 and Spe1 restriction sites. The cDNA encoding a constitutively active version of the human TGFBR1 kinase domain (residues 175–503 with a T204D mutation) was cloned into the MCSII using the SmaI and SphI restriction sites. A high-titre baculovirus (>108 pfu/ml) was generated using standard published protocols (Fitzgerald et al., 2006). Expression of the trimeric phosphorylated SMAD2 MH2 domain was performed by infecting Sf21 cells at a density of 1.5 × 106 cells/ml at a MOI: 1 and incubating for 72 hr at 27°C with rotation at 110 r.p.m. Cells were harvested by centrifugation at 1000 × g for 10 min and stored at −80°C until required.

Expression of the human phosphorylated SMAD3–SMAD4 complex

Request a detailed protocol

An expression construct was generated encoding GST-fused full-length human SMAD3 (with 3C protease site) and inserted into the MCSI of the pFastBac dual. As with the SMAD2 MH2 domain construct, the constitutively active human TGFBR1 kinase domain was cloned into MCSII. Another vector encoding full-length human SMAD4 alone was also constructed, where SMAD4 was inserted into the pBacPAK plasmid. The resulting vectors were used to generate high-titre virus (>108 pfu/ml) using a standard published protocol. For expression of the phosphorylated SMAD3–SMAD4 complex both viruses were used to infect cultures of Sf21 insect cells at a density of 1.5 × 106 cells/ml at a MOI: 1. Infected cultures were allowed to grow for 72 hr at 27°C with rotation at 110 r.p.m. Cells were harvested by centrifugation at 1000 x g for 10 min and stored at −80°C until required.

Purification of trimeric phosphorylated SMAD2 MH2 domain and phosphorylated SMAD3–SMAD4 complexes

Request a detailed protocol

The same procedure was used to purify both phosphorylated SMAD2 MH2 domain trimers and phosphorylated SMAD3–SMAD4 complexes. Typically, 500 ml of infected Sf21 cells were lysed in 30 ml of a lysis buffer consisting of 50 mM HEPES (pH 8.0), 250 mM NaCl, 10% (vol/vol) glycerol, 1% (vol/vol) Triton X-100, 10 mM β-glycerophosphate, 1 mM NaF, 10 mM benzamidine, and 1 mM dithiothreitol (DTT) supplemented with 5 µl BaseMuncher (2500 U/µl), 5 mM MgCl2, and phosphatase (phosphatase inhibitor cocktail 3, Sigma) and protease inhibitors (EDTA-free cOmplete protease inhibitors, Roche). After incubation for 20 min, the suspension was sonicated to ensure complete lysis. The insoluble fraction was pelleted by centrifugation (100,000 × g at 4°C for 30 min). The soluble fraction was incubated with 500 µl bed volume of Glutathione 4B Sepharose (Cytiva) for 2 hr at 4°C with gentle agitation. The resin was washed extensively with buffer containing 50 mM HEPES (pH 7.5), 200 mM NaCl, and 1 mM DTT. The phosphorylated SMAD2 MH2 domain or phosphorylated SMAD3–SMAD4 complexes were eluted from the GSH resin by cleavage with GST-3C protease (20 µg) in 5 ml wash buffer overnight at 4°C with gentle agitation. The proteins were concentrated to 0.5 ml and applied to a S200 10/300 Increase (Cytiva) size exclusion column equilibrated with 50 mM HEPES (pH 7.5), 200 mM NaCl, 5% (vol/vol) glycerol, and 1 mM DTT. Fractions were analyzed by SDS–PAGE and concentrated to 2 mg/ml and snap frozen as 50 µl aliquots and stored at −80°C until required. Purified phosphorylated SMAD2 MH2 domain was quantified using a molar extinction coefficient value of 39,420 M−1cm−1. The molar extinction coefficients used for SMAD3 and SMAD4 were 68,870 and 70,820 M−1cm−1, respectively.

Size exclusion chromatography with multiangle laser light scattering

Request a detailed protocol

The trimeric arrangement of the phosphorylated SMAD2 MH2 domain was confirmed by SEC-MALLS. In brief, an S200 10/300 Increase column was attached to an AKTA Micro FPLC system (GE Healthcare), which was connected to a Heleos Dawn 8+ followed by an Optilab TRex (Wyatt). For data collection, 100 µl of a 2 mg/ml stock of phosphorylated SMAD2 MH2 domain was injected and data collected at 0.5 ml/min for 60 min. The data were analyzed by ASTRA6.1 software.

Biolayer interferometry

Request a detailed protocol

Biolayer interferometry was carried out using an Octet RED96 instrument (ForteBio). Biotinylated N-SKI peptide (residues 11–45) was immobilized on streptavidin-coated biosensors (ForteBio) at a concentration of 1 μg/ml in buffer containing 50 mM HEPES pH 7.5, 200 mM NaCl, 1 mg/ml bovine serum albumin, and 0.1% Tween-20 for 100 s. The immobilization typically reached a response level of 2 nm. Association and dissociation curves were obtained through addition of a dilution series of trimeric phosphorylated SMAD2 MH2 domain complex (15.6–1.95 μM) for 100 s followed by dissociation in buffer for 350 s using the Octet acquisition software. The binding data were fitted using the Octet analysis software.

Crystallization of the N-SKI–SMAD2 MH2 domain complex

Request a detailed protocol

The SKI peptide (amino acids 11–45) was synthesized by the Peptide Chemistry Group and added in a 2:1 ratio to the phosphorylated SMAD2 MH2 domain trimer. The complex was concentrated to 6 mg/ml and subject to crystallization trials. Initial screening gave rise to fine needles, in several conditions, and these were used as seedstock for rescreening. This gave rise to 25 µm crystals, with a cubic morphology, in the Crystal Screen Cryo screen (Hampton Research); the condition being 1.5 M ammonium sulphate, 0.15 M K Na tartrate, 0.08 M Na3citrate, and 25% (vol/vol) glycerol. The crystals were flash-frozen in liquid nitrogen, and data were collected on the I24 beamline at Diamond Light Source (DLS). Data was processed automatically using the DLS Xia2/XDS pipeline (Winter, 2010; Kabsch, 2010). The crystals belong to the I213 space group and diffracted to a resolution of 2.0 Å.

Structure determination

Request a detailed protocol

Molecular replacement was undertaken with the CCP4 program Phaser (McCoy et al., 2007), utilising pdbfile 1khx (with the C-terminal tail removed), as the search model (Winn et al., 2011). Initial structure refinement was undertaken with Refmac (Murshudov et al., 2011), with manual model building in Coot (Emsley et al., 2010), before switching to Phenix.Refine to finalize the model (Liebschner et al., 2019; Afonine et al., 2012). Coordinates and data are available from the Protein Data Bank, with accession code: 6ZVQ.

RNA extraction, qRT-PCR, and RNA-sequencing

Request a detailed protocol

Total RNA was extracted using Trizol (Thermo Fisher Scientific) according to the manufacturer’s instructions. cDNA synthesis and qPCRs were performed as described (Grönroos et al., 2012). Primer sequences are listed in Key Resources Table. All qPCRs were performed with the PowerUp SYBR Green Master Mix (Thermo Fisher Scientific) with 300 nM of each primer and 2 µl of diluted cDNA. Fluorescence acquisition was performed on either a 7500 FAST machine or QuantStudio 12 Flex (Thermo Fisher Scientific). Calculations were performed using the ΔΔCt method, and levels of mRNA are expressed as fold change relative to untreated or SB-431542-treated control cells. Means ± SEM from at least three independent experiments are shown. Results were analyzed using GraphPad Prism 8 software and statistics were performed on these data using one-way or two-way analysis of variance (ANOVA) as stated in the figure legends.

For the RNA-sequencing experiment four biological replicates were used. Total RNA was extracted, and the quality of the RNA was assessed using a bioanalyzer (Agilent). Libraries were prepared using the KAPA mRNA HyperPrep kit (Roche), and single-end reads were generated using an Illumina HiSeq 4000.

RNA sequencing analysis

Request a detailed protocol

Raw reads were quality and adapter trimmed using cutadapt-1.9.1 (Martin, 2011) prior to alignment. Reads were then aligned and quantified using RSEM-1.3.0/STAR-2.5.2 (Dobin et al., 2013; Li and Dewey, 2011) against the human genome GRCh38 and annotation release 89, both from Ensembl. TPM (transcripts per kilobase million) values were also generated using RSEM/STAR. Differential gene expression analysis was performed in R-3.6.1 (R Development Core Team, 2009) using the DESeq2 package (version 1.24.0) (Love et al., 2014). Differential genes were selected using a 0.05 false discovery rate threshold using the pairwise comparisons between time points within each cell line individually. Normalization and variance-stabilizing transformation was applied on raw counts before performing principal component analysis and Euclidean distance-based clustering.

For the heatmaps, we selected those genes that were significantly differentially expressed in the control cell line with an absolute log2 (fold change) of at least 0.5, not significantly differentially expressed in the SKI-mutated cell lines, and detected with at least a TPM value of 2 in the control cell lines in any condition. We then visualized the log2 (fold change) for each time point against the control condition. Heatmaps were generated in R-3.6.1 using the ComplexHeatmap (Gu et al., 2016) package (version 2.0.0). The raw data files have been uploaded to the European Genome-phenome Archive (EGA), accession number EGAS00001004908.

Quantifications

Request a detailed protocol

Quantification of Western blots was performed by densitometry measurements of each lane using ImageJ software. The measurements were normalized to the loading control in the same blot. In each case, quantifications were normalized to the SB-431542-treated samples. Quantification for the flow cytometry was performed by measurement of the fluorescence emitted by Alexa 647 in EGFP-expressing single cells as a measure of SKIL protein, and levels were normalized to the SB-431542-treated sample in the SMAD4 knockout cells. The program FlowJo was used to analyze the results. For the peptide arrays, two independent experiments were quantified. The staining intensity of each array was quantified by systematically moving a circular selection (diameter 20 pixels) across the array and measuring the 8-bit greyscale intensity for each spot. Each intensity measure was normalized to the average intensity of 60 positive controls of the WT peptide after subtracting the background, measured from the average intensity of 60 negative controls (truncated SKI peptide C as indicated in Figure 4—figure supplement 1B).

Statistical analysis

Request a detailed protocol

Statistical analysis was performed in Prism 8 (GraphPad). At least three independent experiments were performed for statistical analysis unless otherwise specified in the figure legends. Normalized values were log transformed for the statistical analysis. For comparison between more than two groups with one variable, one-way ANOVA was used followed by the Sidak’s correction test. For comparison between groups that have been split on two independent variables, two-way ANOVA was performed followed by Tukey’s multiple comparison tests.

Appendix 1

Appendix 1—key resources table
Reagent type (species)
or resource		DesignationSource or referenceIdentifiersAdditional information
Cell line (Homo sapiens)HaCaTFrancis Crick Institute
Cell Services		RRID:CVCL_0038Keratinocytes (immortalized adult)
Cell line (Homo sapiens)HEK293TFrancis Crick Institute
Cell Services		RRID:CVCL_0063Embryonic kidney cells (normal)
Cell line (Homo sapiens)Dermal fibroblasts
(normal, adult)		David Abraham, UCL, UKPrimary cells, male
Cell line (Homo sapiens)Dermal fibroblasts
(carrying heterozygous
mutation L32V SKI)		Carmignac et al., 2012
PMID:23103230		Primary cells, female
Cell line (Homo sapiens)Dermal fibroblasts
(carrying heterozygous
mutation ΔS94-97 SKI)		Carmignac et al., 2012
PMID:23103230		Primary cells, male
Cell line (Homo sapiens)HaCaT S4 KO #1;
HaCaT S4 KO #2;
HaCaT S4 KO #3;
HaCaT S4 KO #4		This paperKeratinocytes in which SMAD4
is deleted by CRISPR/Cas9
technology
Cell line (Homo sapiens)HEK293T S2 KO #1;
HEK293T S2 KO #2		This paperEmbryonic kidney cells in which
SMAD2 is deleted by
CRISPR/Cas9 technology
Cell line (Homo sapiens)HEK293T S3 KO #1;
HEK293T S3 KO #2		This paperEmbryonic kidney cells in which
SMAD3 is deleted by
CRISPR/Cas9 technology
Cell line (Homo sapiens)HEK293T S2/S3 dKO #1;
HEK293T S2/S3 dKO #2		This paperEmbryonic kidney cells in which
SMAD2 and SMAD3 are deleted
simultaneously by
CRISPR/Cas9 technology
Cell line (Homo sapiens)HEK293T S4 KO #1;
HEK293T S4 KO #2		This paperEmbryonic kidney cells in which
SMAD4 is deleted by
CRISPR/Cas9 technology
Cell line (Homo sapiens)HEK293T P35S SKI #1;
HEK293T P35S SKI #2;
HEK293T P35S SKI #3;
HEK293T P35S SKI #4		This paperEmbryonic kidney cells in which
the P35S SKI mutation is
introduced by
CRISPR/Cas9 technology
Cell line (Homo sapiens)HEK293T
CAGA12-Luciferase/Renilla		This paperEmbryonic kidney cells in which
the CAGA12-Luciferase and
TK-Renilla reporters
are stably expressed
Cell line (Homo sapiens)HEK293T
BRE-Luciferase/Renilla		This paperEmbryonic kidney cells in which
the BRE-Luciferase and TK-Renilla
reporters are stably expressed
Cell line (Homo sapiens)HEK293T P35S SKI
CAGA12 Luciferase/Renilla #2;
HEK293T P35S SKI
CAGA12 Luciferase/Renilla #3		This paperHEK293T P35S SKI clones 2 and 3 in
which the CAGA12-Luciferase and
TK-Renilla reporters are
stably expressed
Cell line (Homo sapiens)HEK293T P35S SKI
BRE-Luciferase/Renilla #2;
HEK293T P35S SKI
BRE-Luciferase/Renilla #3		This paperHEK293T P35S SKI clones 2 and 3 in
which the BRE-Luciferase and
TK-Renilla reporters are
stably expressed
Cell line (Homo sapiens)HaCaT S4 KO EGFPThis paperHaCaT SMAD4 KO clone 2 cells
stably expressing EGFP
Cell line (Homo sapiens)HaCaT SMAD4 KO rescue
EGFP-SMAD4 WT		This paperHaCaT SMAD4 KO clone 2 cells stably
expressing EGFP-SMAD4 WT
Cell line (Homo sapiens)HaCaT SMAD4 KO rescue
EGFP-SMAD4 D351H		This paperHaCaT SMAD4 KO clone 2 cells stably
expressing EGFP-SMAD4 D351H
Cell line (Homo sapiens)HaCaT SMAD4 KO rescue
EGFP-SMAD4 D537Y		This paperHaCaT SMAD4 KO clone 2 cells stably
expressing EGFP-SMAD4 D537Y
Cell line (Homo sapiens)HaCaT SMAD4 KO
rescue
EGFP-SMAD4 A433E		This paperHaCaT SMAD4 KO clone 2 cells stably
expressing EGFP-SMAD4 A433E
Cell line (Homo sapiens)HaCaT SMAD4 KO
rescue
EGFP-SMAD4 I435Y		This paperHaCaT SMAD4 KO clone 2 cells stably
expressing EGFP-SMAD4 I435Y
Cell line (M. musculus)MEF SMAD2Δex2Piek et al., 2001
PMID:11262418		Mouse embryo-derived fibroblasts
carrying the homozygous
null allele Smad2ex2
Cell line
(Spodoptera frugiperda)		Sf21Fitzgerald et al., 2006
PMID:17117155		Insect cells used to express
recombinant proteins
Transfected constructpGFP-C1VectorBuilderClontech,
Cat# 6084–1		Construct used to make HaCaT
SMAD4 KO stably expressing EGFP
Transfected
construct (human)		pEGFP-SMAD4 WTNicolás et al., 2004
PMID:15280432		Construct used to make HaCaT
SMAD4 KO stably expressing
EGFP SMAD4 WT
Transfected
construct (human)		pEGFP-SMAD4 D351HThis paperConstruct used to make HaCaT
SMAD4 KO stably expressing
EGFP-SMAD4 D351H
Transfected
construct (human)		pEGFP-SMAD4 D537YThis paperConstruct used to make HaCaT
SMAD4 KO stably expressing
EGFP-SMAD4 D537Y
Transfected
construct (human)		pEGFP-SMAD4 A433EThis paperConstruct used to make HaCaT
SMAD4 KO stably expressing
EGFP-SMAD4 A433E
Transfected
construct (human)		pEGFP-SMAD4 I435YThis paperConstruct used to make HaCaT
SMAD4 KO stably expressing
EGFP-SMAD4 I435Y
Transfected constructpRL-TK VectorPromegaCat# E2241Construct used to make HEK
293T cells stably expressing
TK Renilla
Transfected constructpGL3-BRE-LucKorchynskyi and ten Dijke, 2002
PMID:11729207		Addgene
Cat# 45126		Construct used to make HEK
293T cells stably expressing
Luciferase under control
of the BRE
Transfected constructpGL3 CAGA12-LucDennler et al., 1998
PMID:9606191		Construct used to make HEK
293T cells stably expressing
Luciferase under control of
the CAGA12 sequence
Transfected constructpSUPER.retro.puroOligoEngineCat# VEC-pRT-0002Construct used to express
resistance to puromycin in order
to make stable cell lines
Transfected constructpSpCas9(BB)−2A-GFP
(PX458)		Ran et al., 2013
PMID:24157548		Addgene Cat# 48138Different oligonucleotides
corresponding to gRNAs have
been cloned into this plasmid
in order to make several different
CRISPR/Cas9 knockout cell lines.
AntibodyAnti-phosphorylated
SMAD2
(Rabbit monoclonal)		Cell Signaling TechnologyCat# 3108;
RRID:AB_490941		WB (1:1000)
AntibodyAnti-SMAD2/3
(mouse monoclonal)		BD BiosciencesCat# 610843;
RRID:AB_398162		IF (1:500)
WB (1:1000)
AntibodyAnti-phospho-SMAD3
(rabbit monoclonal)		Cell Signaling TechnologyCat# 9520;
RRID:AB_2193207		WB (1:500)
AntibodyAnti-SMAD4 (B-8)
(mouse monoclonal)		Santa CruzCat# sc-7966;
RRID:AB_627905		WB (1:1000)
AntibodyAnti-SMAD3
(Rabbit monoclonal)		AbcamCat# 40854;
RRID:AB_777979		WB (1:1000)
AntibodyAnti-FLAG DYKDDDDK
Tag (L5)
(Rat monoclonal)		Thermo FisherCat# MA1-142,
RRID:AB_2536846		IP (5 µg)
WB (1:1000)
AntibodyAnti-MCM6 (C-20)
(Goat polyclonal)		Santa CruzCat# sc-9843;
RRID:AB_2142543		WB (1:2000)
AntibodyAnti MCM6 (H-8)
(Mouse monoclonal)		Santa CruzCat# sc-393618
RRID:AB_2885187		WB (1:2000)
AntibodyAnti-Tubulin
(Rat monoclonal)		AbcamCat# ab6160;
RRID:AB_305328		WB (1:5000)
AntibodyAnti-SKI
(Rabbit Polyclonal)		GeneTexCat# GTX133764
RRID:AB_2885186		IP (5 µg)
WB (1:2000)
AntibodyAnti-GFP
(Goat polyclonal)		AbcamCat# ab6673,
RRID:AB_305643		IF (1:200)
AntibodyAnti SKIL (SnoN)
(H-317)
(Rabbit polyclonal)		Santa CruzCat# sc-9141,
RRID:AB_671124		WB (1:1000)
IF (1:1000)
Flow cytometry (1:200)
AntibodyDonkey anti-Goat IgG
(H+L) Cross-adsorbed
secondary antibody,
Alexa Fluor 546		Thermo Fisher ScientificCat# A-11056,
RRID:AB_2534103		IF (1:1000)
antibodyAnti-Rabbit Alexa Fluor 594Thermo Fisher ScientificCat# A-21244;
RRID:AB_10562581		IF (1:1000)
AntibodyAnti-Rabbit Alexa Fluor 647Thermo Fisher ScientificCat# A-21244,
RRID:AB_2535812		Flow cytometry (1:1000)
AntibodyGoat anti-rabbit HRPDakoCat# P0448;
RRID:AB_2617138		WB (1:5000)
AntibodyGoat anti-mouse HRPDakoCat#P0447;
RRID:AB_2617137		WB (1:5000)
AntibodyDonkey anti-rat HRPJackson LabCat#712-035-153;
RRID:AB_2340639		WB (1:5000)
AntibodyRabbit anti-goat HRPDakoCat# P0449,
RRID:AB_2617143		WB (1:5000)
Recombinant DNA reagentpEF-FLAG-SKIL
(plasmid)		This paperTransient transfection in
HEK293T cells to
express FLAG SKIL WT
Recombinant DNA reagentFLAG SKIL
G103V (SKIL ΔS2/S3)
(plasmid)		This paperTransient transfection in
HEK293T cells to
express FLAG SKIL G103V
Recombinant DNA reagentFLAG SKIL R314A,
T315A, H317A,
W318E (SKIL ΔS4)
(plasmid)		This paperTransient transfection in
HEK293T cells to express
FLAG SKIL R314A,
T315A, H317A, W318E
Recombinant DNA reagentpFast Dual
ALK5* GST-MH2-hSMAD2
(plasmid)		This paperUsed to express recombinant
proteins in insect cells
Recombinant DNA reagentpFastDual
ALK5*/GST-hSMAD3
(plasmid)		This paperUsed to express recombinant
proteins in insect cells
Recombinant DNA reagentpBacPAK-SMAD4
(plasmid)		This paperUsed to express recombinant
proteins in insect cells
Sequence-based reagentSMAD4_F1This paperCACCGACAACTCGTTCGTAGTGATA
CRISPR/Cas9-mediated knockout
guide, forward oligo 1
Sequence-based reagentSMAD4_R1This paperAAACTATCACTACGAACGAGTTGTC
CRISPR/Cas9 mediated knockout
guide, reverse oligo 1
Sequence-based reagentSMAD4_F2This paperCACCGTGAGTATGCATAAGCGACGA
CRISPR/Cas9 mediated knockout
guide, forward oligo 2
Sequence-based reagentSMAD4_R2This paperAAACTCGTCGCTTATGCATACTCAC
CRISPR/Cas9 mediated knockout
guide, reverse oligo 2
Sequence-based reagentSMAD2 _F1This paperCACCGCTATCGAACACCAAAATGC
CRISPR/Cas9 mediated knockout
guide, forward oligo
Sequence-based reagentSMAD2 _R1This paperAAACGCATTTTGGTGTTCGATAGC
CRISPR/Cas9 mediated knockout
guide, reverse oligo
Sequence-based reagentSMAD3_F1This paperCACCGGAATGTCTCCCCGACGCGC
CRISPR/Cas9 mediated knockout
guide, forward oligo
Sequence-based reagentSMAD3_R1This paperAAACGCGCGTCGGGGAGACATTCC
CRISPR/Cas9 mediated knockout
guide, reverse oligo
Sequence-based reagentSKI_F1This paperCACCGCAGCGCGCCGAGAAAGCGGC
CRISPR/Cas9 mediated knockin
guide, forward oligo
Sequence-based reagentSKI_R1This paperAAACGCCGCTTTCTCGGCGCGCTGC
CRISPR/Cas9 mediated knockin
guide, reverse oligo
Sequence-based reagentSKI_ssODNThis paperG*C*AGTTCCACCTGAGCTCCATGAGC
TCGCTGGGAGGATCCGCCGCTTTCTC
GGCGCGCTGGGCGCAGGAGGCCTA
CAAGAAGGAGAGCGCCAAGGAGGCG
GGCGCGGCCGCGGTGCCG*G*C
Repair template
Sequence-based reagentSKI_R2This paperGCCCATGACTTTGAGGATCTCC
Universal reverse primer for
clone screening
Sequence-based reagentSKI_F2This paperATGAGCTCGCTGGGCGGCCCG
WT SKI forward primer
for clone screening
Sequence-based reagentSKI_F3This paperATGAGCTCGCTGGGAGGATCC
P35S SKI forward primer
for clone screening
Sequence-based reagentBiotinylated WT cJUN
SBE oligonucleotide (top)		Levy et al., 2007
PMID:17591695		5′-Biotin-
GGAGGTGCGCGGAGTCAGG
CAGACAGACAGACACAGCCA
GCCAGCCAGGTCGGCA
DNAP oligo - Top
Sequence-based reagentWT cJUN SBE
oligonucleotide (bottom)		Levy et al., 2007
PMID:17591695		TGCCGACCTGGCTGGCTGGC
TGTGTCTGTCTGTCTGCCTG
ACTCCGCGCACCTCC
DNAP oligo - Bottom
Sequence-based reagentBiotinylated MUT cJUN
SBE oligonucleotide (top)		This paper5′-biotin-
GGATTTGCTAATGATATAGT
AATATATATATATACATATAT
ATATATTGATCTTCA
Mutated DNAP oligo -Top
Sequence-based reagentMUT cJUN
SBE oligonucleotide (bottom)		This paperTGAAGATCAATATATATATAT
GTATATATATATATTACTAT
ATCATTAGCAAATCC
Mutated DNAP oligo -Bottom
Sequence-based reagentMUT cJUN SBE
oligo-nucleotide (top)		This paperGGATTTGCTAATGATATAGTA
ATATATATATATACATATAT
ATATATTGATCTTCA
Competitor mutant oligo - Top
Sequence-based reagentMUT cJUN SBE
oligo-nucleotide (bottom)		This paperTGAAGATCAATATATATATATG
TATATATATATATTACTATA
TCATTAGCAAATCC
Competitor mutant
oligo – bottom
Sequence-based reagentGAPDH_F1Grönroos et al., 2012
PMID:22615489		CTTCAACAGCGACACCCACT
PCR primer
Sequence-based reagentGAPDH_R1Grönroos et al., 2012
PMID:22615489		GTGGTCCAGGGGTCTTACTC
PCR primer
Sequence-based reagentSMAD7_F1Grönroos et al., 2012
PMID:22615489		CTTAGCCGACTCTGCGAACT
PCR primer
Sequence-based reagentSMAD7_R1Grönroos et al., 2012
PMID:22615489		CCAGGCTCCAGAAGAAGTTG
PCR primer
Sequence-based reagentSKIL_F1This paperCTGGGGCTTTGAATCAGCTA
PCR primer
Sequence-based reagentSKIL_R1This paperCATGGTCACCTTCCTGCTTT
PCR primer
Sequence-based reagentSERPINE1_F1Grönroos et al., 2012
PMID:22615489		TGATGGCTCAGACCAACAAG
PCR primer
Sequence-based reagentSERPINE1_R1Grönroos et al., 2012
PMID:22615489		GTTGGTGAGGGCAGAGAGAG
PCR primer
Sequence-based reagentJUNB_F1Ramachandran et al., 2018
PMID:29376829		ATACACAGCTACGGGATACGG
PCR primer
Sequence-based reagentJUNB_R1Ramachandran et al., 2018
PMID:29376829		GCTCGGTTTCAGGAGTTTGT
PCR primer
Sequence-based reagentID1_F1Ramachandran et al., 2018
PMID:29376829		GCCGAGGCGGCATGCGTTC
PCR primer
Sequence-based reagentID1_R1Ramachandran et al., 2018
PMID:29376829		CTTGCCCCCTGGATGGCTGG
PCR primer
Sequence-based reagentID3_F1Grönroos et al., 2012
PMID:22615489		GGCCCCCACCTTCCCATCC
PCR primer
Sequence-based reagentID3_R1Grönroos et al., 2012
PMID:22615489		GCCAGCACCTGCGTTCTGGAG
PCR primer
Sequence-based reagentCDKN1A_F1Miller et al., 2018
PMID:30428352		ACTCTCAGGGTCGAAAACGG
PCR primer
Sequence-based reagentCDKN1A_R1Miller et al., 2018
PMID:30428352		ATGTAGAGCGGGCCTTTGAG
PCR primer
Sequence-based reagentISLR2_F1This paperAGTCGGCGAATATTGGGAGC
PCR primer
Sequence-based reagentISLR2_R1This paperATGATCCGGCCACTCCTAGA
PCR primer
Sequence-based reagentCALB2_F1This paperATGGCAAATTGGGCCTCTCA
PCR primer
Sequence-based reagentCALB2_R1This paperGGTCAGCTTCATGCCCTGAAAT
PCR primer
Sequence-based reagentSOX11_F1This paperAGCGGAGGAGGTTTTCAGTG
PCR primer
Sequence-based reagentSOX11_R1This paperTTCCATTCGGTCTCGCCAAA
PCR primer
Sequence-based reagentITGB6_F1This paperTGCGACCATCAGTGAAGAAG
PCR primer
Sequence-based reagentITGB6_R1This paperGACAACCCCGATGAGAAGAA
PCR primer
Sequence-based reagentHEY1_F1This paperGCTTTTGAGAAGCAGGGATCT
PCR primer
Sequence-based reagentHEY1_R1This paperGATAACGCGCAACTTCTGCC
PCR primer
Sequence-based reagentCOL7A1_F1This paperCAAGGGGGACATGGGTGAAC
PCR primer
Sequence-based reagentCOL7A1_R1This paperCGGATACCAGGCACTCCATC
PCR primer
Sequence-based reagentSMAD4_F3This paperGTTCATAAGATCTACCCAAGTG
AATATATAAAGGTCTTTGATTTG
PCR primer for cloning,
forward primer carrying
the mutation A433E
Sequence-based reagentSMAD4_R3This paperACGCAAATCAAAGACCTTTATA
TATTCACTTGGGTAGATCTTATG
PCR primer for cloning,
reverse primer carrying
the mutation A433E
Sequence-based reagentSMAD4_F4This paperAAGATCTACCCAAGTGCATATT
ACAAGGTCTTTGATTTGCGTCAG
PCR primer for cloning,
forward primer carrying
the mutation I435Y
Sequence-based reagentSMAD4_R4This paperCTGACGCAAATCAAAGACCTTGT
AATATGCACTTGGGTAGATCTT
PCR primer for cloning,
reverse primer carrying
the mutation I435Y
Sequence-based reagentSKIL_F2This paperCAGAGCTCGCTGGGTGTA
CCAGCAGCATTTTC
PCR primer for cloning,
forward primer carrying
the mutation G103V
Sequence-based reagentSKIL_R2This paperGAAAATGCTGCTGGTAC
ACCCAGCGAGCTCTG
PCR primer for cloning,
reverse primer carrying
the mutation G103V
Peptide,
recombinant protein		SKI peptide AThis paperBiotin-aminohexanoic
acid-
FQPHPGLQKTLEQFHLSSMSS
LGGPAAFSARWAQEAYKKES
Peptide,
recombinant protein		SKI peptide BThis paperBiotin-aminohexanoic
acid-
FQPHPGLQKTLEQFHLS
SMSSLGGPAAFSARWAQE
Peptide,
recombinant protein		SKI peptide CThis paperBiotin-aminohexanoic
acid-
GLQKTLEQFHLSSMSSLG
GPAAFSARWAQE
Peptide,
recombinant protein		SKI peptide DThis paperBiotin-aminohexanoic
acid-
TLEQFHLSSMSSLGG
PAAFSARWAQE
Peptide,
recombinant protein		SKI peptide EThis paperBiotin-aminohexanoic
acid-
TLEQFHLSSMSSLGGPA
AFSARWAQEAYK
Peptide,
recombinant protein		SKI L21RThis paperBiotin-aminohexanoic
acid-
FQPHPGLQKTREQFHLSS
MSSLGGPAAFSARWAQE
Peptide,
recombinant protein		SKI S28TThis paperBiotin-aminohexanoic
acid-
FQPHPGLQKTLEQFHLS
TMSSLGGPAAFSARWAQE
Peptide,
recombinant protein		SKI S31LThis paperBiotin-aminohexanoic
acid-
FQPHPGLQKTLEQFHLS
SMSLLGGPAAFSARWAQE
Peptide,
recombinant protein		SKI L32PThis paperBiotin-aminohexanoic
acid-
FQPHPGLQKTLEQFHLS
SMSSPGGPAAFSARWAQE
Peptide,
recombinant protein		SKI G34DThis paperBiotin-aminohexanoic
acid –
FQPHPGLQKTLEQFHLSS
MSSLGDPAAFSARWAQE
Peptide,
recombinant protein		SKI P35SThis paperBiotin-aminohexanoic
acid –
FQPHPGLQKTLEQFHLSS
MSSLGGSAAFSARWAQE
Peptide,
recombinant protein		SKIL WTThis paperBiotin-aminohexanoic
acid –
LHLNPSLKHTLAQFHLSSQSS
LGGPAAFSARHSQESMSPTV
Peptide,
recombinant protein		SKIL L90RThis paperBiotin-aminohexanoic
acid –
LHLNPSLKHTRAQFHLSSQS
SLGGPAAFSARHSQESMSPTV
Peptide,
recombinant protein		SKIL S100LThis paperBiotin-aminohexanoic
acid -
LHLNPSLKHTLAQFHLSSQS
LLGGPAAFSARHSQESMSPTV
Peptide,
recombinant protein		SKIL G103DThis paperBiotin-aminohexanoic
acid -
LHLNPSLKHTLAQFHLSSQSS
LGDPAAFSARHSQESMSPTV
Peptide,
recombinant protein		SKIL P104SThis paperBiotin-aminohexanoic
acid -
LHLNPSLKHTLAQFHLSSQSS
LGGSAAFSARHSQESMSPTV
Peptide,
recombinant protein		SKI WTThis paperFQPHPGLQKTLEQFHLSSMSS
LGGPAAFSARWAQE
Peptide,
recombinant
protein		Human recombinant TGF-β1PeprotechCat# 100–21
Peptide,
recombinant
protein		Human recombinant BMP4PeprotechCat# 120-05ET
Peptide,
recombinant
protein		Human recombinant Activin APeprotechCat# 120–14
Commercial assay or kitPowerUp SYBR
Green Master Mix		Thermo Fisher ScientificCat# A25742
Commercial assay or kitQuickextract DNA
extraction solution		LucigenCat# QE09050
Commercial assay or kitDual-Glo Luciferase
Assay System		PromegaCat# E2920
Commercial assay or kitFugene 6 transfection
reagent		PromegaCat# E2691
Commercial assay or kitSuperdex 200 10/300
size exclusion column		CytivaCat# 28990944
Commercial assay or kitStreptavidin (SA) BiosensorsForteBioCat# 18–5019
Commercial assay or kitGlutathione 4B SepharoseCytivaCat# 17075601
Commercial assay or kitPierce NeutrAvidin AgaroseThermo Fisher ScientificCat# 29200
Commercial assay or kitGFP-Trap Agarose (IP)CromotekCat# gta-20
Commercial assay or kitProtein G
Sepharose, Fast Flow		Sigma–AldrichCat# P3296
Chemical compound, drugcOmplete, EDTA-free
Protease Inhibitor Cocktail		Sigma–AldrichCat#
000000011873580001
Chemical compound, drugTRIzolThermo Fisher ScientificCat# 15596026
Chemical compound, drugDAPISigma-AldrichCat# 10236276001
Chemical compound, drugSB-431542Tocris; Inman et al., 2002:
PMID:12065756		Cat# 1614
Chemical compound, drugMG-132TocrisCat# 1748
Software, algorithmFIJI (ImageJ)https://imagej.net/Fiji/DownloadsRRID:SCR_002285
Software, algorithmFlowJo 10FlowJoRRID:SCR_008520
Software, algorithmGraphPad Prism 8GraphPadRRID:SCR_002798
Software, algorithmASTRA6.1WyattRRID:SCR_001625
Software, algorithmOctet CFR softwareForteBio
Software, algorithmDLS Xia2/XDS pipelineWinter, 2010;
Kabsch, 2010
PMID:20124692
Software, algorithmCCP4 suiteWinn et al., 2011
PMID:21460441		RRID:SCR_007255
Software, algorithmPhaserMcCoy et al., 2007
PMID:19461840		RRID:SCR_014219
Software, algorithmRefmacMurshudov et al., 2011
PMID:21460454		RRID:SCR_014225
Software, algorithmCootEmsley et al., 2010
PMID:20383002		RRID:SCR_014222
Software, algorithmPHENIX SuiteLiebschner et al., 2019
PMID:31588918		RRID:SCR_014224
Software, algorithmPhenix.RefineAfonine et al., 2012
PMID:22505256		RRID:SCR_016736
Software, algorithmRSEM-1.3.0/STAR-2.5.2Li and Dewey, 2011;
PMID:21816040
Dobin et al., 2013
PMID:23104886		RRID:SCR_013027
Software, algorithmDESeq2 package
(version 1.24.0)		Love et al., 2014
PMID:25516281		RRID:SCR_015687

Data availability

Sequencing data have been uploaded to the European Genome-phenome Archive (EGA), accession number EGAS00001004908. Diffraction data have been deposited in PDB under the accession code 6ZVQ. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1, 2, 4, 5, 6, 7, Figure 1 Supplement 1, Figure 2 Supplement 1, Figure 7 Supplement 2.

The following data sets were generated
    1. Gori I
    2. George R
    3. Purkiss AG
    4. Strohbuecker S
    5. Randall RA
    6. Ogrodowicz R
    7. Carmignac V
    8. Faivre L
    9. Joshi D
    10. Kjær S
    11. Hill CS
    (2020) European Genome-Phenome Archive
    ID EGAS00001004908. Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization.
    https://www.ebi.ac.uk/ega/studies/EGAS00001004908
    1. Purkiss AG
    2. Kjær S
    3. George R
    4. Hill CS
    (2020) RCSB Protein Data Bank
    ID 6ZVQ. Complex betweenSMAD2 MH2 domain and peptide from Ski corepressor.
    https://www.rcsb.org/structure/6ZVQ

References

    1. Emsley P
    2. Lohkamp B
    3. Scott WG
    4. Cowtan K
    (2010) Features and development of coot
    Acta Crystallographica. Section D, Biological Crystallography 66:486–501.
    https://doi.org/10.1107/S0907444910007493
    1. Kabsch W
    (2010) XDS
    Acta Crystallographica. Section D, Biological Crystallography 66:125–132.
    https://doi.org/10.1107/S0907444909047337
    1. Massagué J
    (2012) TGFβ signalling in context
    Nature Reviews Molecular Cell Biology 13:616–630.
    https://doi.org/10.1038/nrm3434
  49. Book
    1. Miller DSJ
    2. Hill CS
    (2016)
    TGF-β superfamily signalling
    In: Bradshaw R. A, Stahl P. D, editors. Encyclopedia of Cell Biology. Elsevier. pp. 1–308.
  59. Software
    1. R Development Core Team
    (2009) R: A language and environment for statistical computing
    R Foundation for Statistical Computing, Vienna, Austria.
    http://www.r-project.org
    1. Shprintzen RJ
    2. Goldberg RB
    (1982)
    A recurrent pattern syndrome of craniosynostosis associated with arachnodactyly and abdominal hernias
    Journal of Craniofacial Genetics and Developmental Biology 2:65–74.

Decision letter

  1. Philip A Cole
    Senior Editor; Harvard Medical School, United States
  2. Roger J Davis
    Reviewing Editor; University of Massachusetts Medical School, United States
  3. David Lambright
    Reviewer; University of Massachusetts Medical School, United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Acceptance summary:

Shprintzen-Goldberg syndrome (SGS) is a multi-systemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys-Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. However, new data from the Hill laboratory reveal that SGS is associated with an attenuation of TGF-β-induced transcriptional responses (not an enhancement) and provide insight into the molecular mechanism. This work has important implications for the treatment of Marfan-related syndromes.

Decision letter after peer review:

Thank you for submitting your article "Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization" for consideration by eLife. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Philip Cole as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as eLife papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

This is an interesting manuscript that demonstrates that SGS-associated mutations in the transcriptional repressor Ski prevent TGFb-induced degradation of Ski. This Ski stabilization is associated with suppression of binding to SMAD2/3 while maintaining repression through an interaction with SMAD4. The conclusions of this study serve to extend established knowledge of SGS-associated Ski mutations and clarify several conflicting/controversial observations related to Marfan-related syndromes more broadly.

In general, this is a strong study and presents good biochemical data using cells with CRISPR-mediated knock-in alleles to mimic SGS-associated Ski mutations as well as patient-derived cell lines. No major criticisms of the study were noted by the reviewers with the exception of a question concerning the structural analysis (Figure 5).

Essential revisions:

1) The crystal structure presented shows an N-terminal Ski peptide in a complex with SMAD2. It is unclear what new information this structure presents since a structure of Ski in complex with Smad2 has previously been reported (Mizazono et al., 2018). The authors should state what conclusions are drawn based on the new data that were not previously based on the Mizazono et al. analysis. It is not obvious that the new structure presented provides new information – if it does, this should be explicitly stated. The presentation and analysis of the structure in the Results and Discussion section of the manuscript should appropriately refer to Mizazono et al. At present, Mizazono et al. is only obliquely cited in the Discussion section of the manuscript.

https://doi.org/10.7554/eLife.63545.sa1

Author response

Essential revisions:

1) The crystal structure presented shows an N-terminal Ski peptide in a complex with SMAD2. It is unclear what new information this structure presents since a structure of Ski in complex with Smad2 has previously been reported (Mizazono et al., 2018). The authors should state what conclusions are drawn based on the new data that were not previously based on the Mizazono et al. analysis. It is not obvious that the new structure presented provides new information – if it does, this should be explicitly stated. The presentation and analysis of the structure in the Results and Discussion section of the manuscript should appropriately refer to Mizazono et al. At present, Mizazono et al. is only obliquely cited in the Discussion section of the manuscript.

We apologize for not referring to the SMAD2–SKI structure published by Miyazono et al., in 2018, in the Results. We have now remedied this. We had actually produced our structure before the publication by Miyazono et al. We think it is very important to publish our structure in this paper, as to our knowledge it is the first SMAD structure to use eukaryotic-cell produced SMAD protein that has been phosphorylated in vivo by co-expression of the kinase domain of the relevant receptor (TGFBR1 in this case). This contrasts with the Miyazono structure that used E. coli produced pseudo-phosphorylated SMAD2 MH2 domain (where glutamic acids are used to mimic phosphates). In addition, our SKI peptide was not tagged, whereas the peptide used for the Miyazono structure has an acidic C-terminal tag. The main features of the structure are similar. This has now been clarified in the Results. We have also referenced the Miyazono paper in the Discussion.

Another advantage of our structure of the phosphorylated SMAD2 MH2 domain is that we have been able to use it to understand why SKI and SKIL only bind to phosphorylated SMAD2 and not to monomeric SMAD2. This issue was not addressed in Miyazono et al., 2018. This too has been clarified in the Results.

https://doi.org/10.7554/eLife.63545.sa2

Article and author information

Author details

  1. Ilaria Gori

    Developmental Signalling Laboratory, The Francis Crick Institute, London, United Kingdom
    Contribution
    Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1913-8520

  2. Roger George

    Structural Biology Facility, The Francis Crick Institute, London, United Kingdom
    Contribution
    Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5547-337X

  3. Andrew G Purkiss

    Structural Biology Facility, The Francis Crick Institute, London, United Kingdom
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5931-3509

  4. Stephanie Strohbuecker

    Bioinformatics and Biostatistics Facility, The Francis Crick Institute, London, United Kingdom
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9781-6879

  5. Rebecca A Randall

    Developmental Signalling Laboratory, The Francis Crick Institute, London, United Kingdom
    Contribution
    Formal analysis, Investigation
    Competing interests
    No competing interests declared

  6. Roksana Ogrodowicz

    Structural Biology Facility, The Francis Crick Institute, London, United Kingdom
    Contribution
    Formal analysis, Investigation
    Competing interests
    No competing interests declared

  7. Virginie Carmignac

    INSERM - Université de Bourgogne UMR1231 GAD, FHU-TRANSLAD, Dijon, France
    Contribution
    Resources
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8802-6448

  8. Laurence Faivre

    INSERM - Université de Bourgogne UMR1231 GAD, FHU-TRANSLAD, Dijon, France
    Contribution
    Resources
    Competing interests
    No competing interests declared

  9. Dhira Joshi

    Peptide Chemistry Facility, The Francis Crick Institute, London, United Kingdom
    Contribution
    Resources, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8660-2528

  10. Svend Kjær

    Structural Biology Facility, The Francis Crick Institute, London, United Kingdom
    Contribution
    Supervision, Project administration
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9767-8683

  11. Caroline S Hill

    Developmental Signalling Laboratory, The Francis Crick Institute, London, United Kingdom
    Contribution
    Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing
    For correspondence
    caroline.hill@crick.ac.uk
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8632-0480

Funding

Francis Crick Institute (FC10095)

  • Ilaria Gori
  • Roger George
  • Andrew G Purkiss
  • Stephanie Strohbuecker
  • Rebecca A Randall
  • Roksana Ogrodowicz
  • Dhira Joshi
  • Svend Kjaer
  • Caroline S Hill

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We would like to thank David Abraham for the normal dermal fibroblasts. We are very grateful to the Francis Crick Institute Advanced Sequencing Facility, the Light Microscopy Facility, the Flow Cytometry Facility, Cell Services, the Genomics Equipment Park and to the Peptide Chemistry Facility. We thank Andrew Economou for quantification of the peptide arrays. We thank all the members of the Hill lab and Davide Coda, Daniel Miller, and Anassuya Ramachandran for helpful discussions and very useful comments on the manuscript. This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001095), the UK Medical Research Council (FC001095), and the Wellcome Trust (FC001095).

Ethics

Human subjects: Dermal fibroblasts from healthy subjects were kindly provided by David Abraham (UCL-Medical School Royal Free Campus) under the ethics of the Health Research Authority, NRES Committee London - Hampstead, Research Ethics Committee (REC) reference, 6398. L32V and ΛS94-97 SKI dermal fibroblasts were obtained from Laurence Faivre and Virginie Carmignac (Université de Bourgogne UMR1231 GAD, Dijon, France) under the ethics of the GAD collection, number DC2011-1332 (Carmignac et al., 2012).

Senior Editor

  1. Philip A Cole, Harvard Medical School, United States

Reviewing Editor

  1. Roger J Davis, University of Massachusetts Medical School, United States

Reviewer

  1. David Lambright, University of Massachusetts Medical School, United States

Publication history

  1. Received: September 28, 2020
  2. Accepted: January 7, 2021
  3. Accepted Manuscript published: January 8, 2021 (version 1)
  4. Version of Record published: January 25, 2021 (version 2)

Copyright

© 2021, Gori et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,246
    Page views
  • 143
    Downloads
  • 6
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ilaria Gori
  2. Roger George
  3. Andrew G Purkiss
  4. Stephanie Strohbuecker
  5. Rebecca A Randall
  6. Roksana Ogrodowicz
  7. Virginie Carmignac
  8. Laurence Faivre
  9. Dhira Joshi
  10. Svend Kjær
  11. Caroline S Hill
(2021)
Mutations in SKI in Shprintzen–Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization
eLife 10:e63545.
https://doi.org/10.7554/eLife.63545

Categories and tags

Research organism

    1. Of interest

    Visualizing molecules of functional human profilin

    Morgan L Pimm et al.
  2. Further reading

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology

    Visualizing molecules of functional human profilin

    Morgan L Pimm et al.
    Research Article Updated

    Profilin-1 (PFN1) is a cytoskeletal protein that regulates the dynamics of actin and microtubule assembly. Thus, PFN1 is essential for the normal division, motility, and morphology of cells. Unfortunately, conventional fusion and direct labeling strategies compromise different facets of PFN1 function. As a consequence, the only methods used to determine known PFN1 functions have been indirect and often deduced in cell-free biochemical assays. We engineered and characterized two genetically encoded versions of tagged PFN1 that behave identical to each other and the tag-free protein. In biochemical assays purified proteins bind to phosphoinositide lipids, catalyze nucleotide exchange on actin monomers, stimulate formin-mediated actin filament assembly, and bound tubulin dimers (kD = 1.89 µM) to impact microtubule dynamics. In PFN1-deficient mammalian cells, Halo-PFN1 or mApple-PFN1 (mAp-PEN1) restored morphological and cytoskeletal functions. Titrations of self-labeling Halo-ligands were used to visualize molecules of PFN1. This approach combined with specific function-disrupting point-mutants (Y6D and R88E) revealed PFN1 bound to microtubules in live cells. Cells expressing the ALS-associated G118V disease variant did not associate with actin filaments or microtubules. Thus, these tagged PFN1s are reliable tools for studying the dynamic interactions of PFN1 with actin or microtubules in vitro as well as in important cell processes or disease-states.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics

    Conformational fingerprinting of allosteric modulators in metabotropic glutamate receptor 2

    Brandon Wey-Hung Liauw et al.
    Research Article

    Activation of G protein-coupled receptors (GPCRs) is an allosteric process. It involves conformational coupling between the orthosteric ligand binding site and the G protein binding site. Factors that bind at non-cognate ligand binding sites to alter the allosteric activation process are classified as allosteric modulators and represent a promising class of therapeutics with distinct modes of binding and action. For many receptors, how modulation of signaling is represented at the structural level is unclear. Here, we developed FRET sensors to quantify receptor modulation at each of the three structural domains of metabotropic glutamate receptor 2 (mGluR2). We identified the conformational fingerprint for several allosteric modulators in live cells. This approach enabled us to derive a receptor-centric representation of allosteric modulation and to correlate structural modulation to the standard signaling modulation metrics. Single-molecule FRET analysis revealed that a NAM increases the occupancy of one of the intermediate states while a PAM increases the occupancy of the active state. Moreover, we found that the effect of allosteric modulators on the receptor dynamics is complex and depend on the orthosteric ligand. Collectively, our findings provide a structural mechanism of allosteric modulation in mGluR2 and suggest possible strategies for design of future modulators.

    1. Biochemistry and Chemical Biology

    A native chemical chaperone in the human eye lens

    Eugene Serebryany et al.
    Research Article Updated

    Cataract is one of the most prevalent protein aggregation disorders and still the most common cause of vision loss worldwide. The metabolically quiescent core region of the human lens lacks cellular or protein turnover; it has therefore evolved remarkable mechanisms to resist light-scattering protein aggregation for a lifetime. We now report that one such mechanism involves an unusually abundant lens metabolite, myo-inositol, suppressing aggregation of lens crystallins. We quantified aggregation suppression using our previously well-characterized in vitro aggregation assays of oxidation-mimicking human γD-crystallin variants and investigated myo-inositol’s molecular mechanism of action using solution NMR, negative-stain TEM, differential scanning fluorometry, thermal scanning Raman spectroscopy, turbidimetry in redox buffers, and free thiol quantitation. Unlike many known chemical chaperones, myo-inositol’s primary target was not the native, unfolded, or final aggregated states of the protein; rather, we propose that it was the rate-limiting bimolecular step on the aggregation pathway. Given recent metabolomic evidence that it is severely depleted in human cataractous lenses compared to age-matched controls, we suggest that maintaining or restoring healthy levels of myo-inositol in the lens may be a simple, safe, and globally accessible strategy to prevent or delay lens opacification due to age-onset cataract.